6th FIP Pharmaceutical Sciences World Congress (PSWC)

Stockholm, Sweden
21-24 May 2017

Future Medicines For One World

Systems approaches to drug discovery, development and clinical usage




Congress Programme



fip

STOCKHOLM PSWC 21-24 May 2017

PSWC 2017
Stockholmsmässan



6th FIP Pharmaceutical Sciences World Congress (PSWC)

Stockholm, Sweden
21-24 May 2017

Congress Programme



Venue
Stockholmsmässan
Mässvägen 1 Älvsjö
125 80 Stockholm
T + 46 8 749 41 00
F +46 8 99 20 44
info@stockholmsmassan.se

Your host
The International Pharmaceutical Federation (FIP)

Your co-hosts
The European Federation for Pharmaceutical Sciences (EUFEPS)
The Swedish Pharmaceutical Society (Apotekarsocieteten)

fip
STOCKHOLM PSWC 21-24 May 2017
EUFEPS
Apotekarsocieteten

We wish to sincerely thank:

aaps
American Association of Pharmaceutical Scientists

Academia Nacional de Farmácia

Apotekarsocieteten

APS
apsgb.org

apsa

BASF
We create chemistry

Bill & Melinda Gates foundation

BIOPERM

AstraZeneca

Conselho Federal de Farmácia

hfd 1858
Hrvatsko farmaceutsko društvo
Croatian Pharmaceutical Society

Douwe D. Breimer Research Foundation

uphar

efpia

European Pharmaceutical Students Association
EPSA

EUFEPS
European Federation for Pharmaceutical Sciences

FIP

FIP Foundation for Education and Research

FREUND VECTOR

GBR
Global Business Reports

DPhG
German Pharmaceutical Society

Ελληνική Φαρμακευτική Εταιρεία
Hellenic Pharmaceutical Society

Societas Scientiarum Pharmaceuticarum Hungarica
Budapest, Condita anno 1924

imi
innovative medicines initiative









































UPPSALA
UNIVERSITET



...for their tremendous support!

WELCOME TO STOCKHOLM

Join leading pharmaceutical scientists from across the globe to discuss cutting-edge research and promising developments.

PSWC will host key discussions on the medicines of the future, addressing questions such as: What will be the breakthroughs and the pitfalls? How can we meet the biggest challenges?

Not only will the congress uphold its world-renowned reputation for top quality speakers, symposia and posters, but we will once again provide a forum for the most extensive international network of pharmaceutical scientists to make an impact on the future of pharmaceutical sciences and global healthcare.

At this congress a start will be made to discuss the future global research agenda.

PSWC 2017 welcomes all

PSWC 2017 will provide scientists from all over the world with a place to meet and network with key leaders from the pharmaceutical industry, government agencies, regulatory bodies, academia and public-private partnerships.
You can listen to, interact with and share the latest research findings in plenary sessions, keynote lectures, short oral sessions, poster sessions and short courses.

PSWC especially also welcomes young scientists. Immediately prior to the main conference, the 'PSWC Young Scientist Satellite Symposium' hosts MSc students in their final year, Pharm Students, PhD students and postdocs, for a programme of keynote lectures, short podium presentations, posters and workshops.

*Please turn this booklet around for the **Young Scientist Satellite Conference Programme***



Future Medicines For One World

Systems approaches to drug discovery, development and clinical usage

We are at a crossroads in medicines research. In the next decade, systems biology research will yield an unprecedented wealth of novel insights in the mechanisms of disease.


This will revolutionise medicines research, leading to the introduction of novel therapeutic interventions which modify and potentially cure disease, rather than providing symptom relief.

At the same time, health systems around the globe are exploring new ways to deliver innovative and sustainable treatment solutions to patients.

You are attending PSWC 2017 to:

- Be at the only truly global pharmaceutical sciences congress in the world
- Meet and network with key opinion leaders in pharmaceutical sciences from all over the world
- Cross-fertilise ideas from all different disciplines present
- Hear high level speakers share their latest research
- Enjoy one of the most beautiful cities in Scandinavia





COMMITTEES

International Scientific Programme Committee



Congress Chair
Meindert Danhof
Leiden University
The Netherlands



Steve Kern
Bill and Melinda Gates Foundation
USA



Giovanni Pauletti
University of Cincinnati
USA



Per Artursson
Uppsala University
Sweden



Bert Leufkens
Utrecht University
The Netherlands



Tomas Salmonsson,
Medical Products Agency
Sweden



Richard Bergström,
European Federation of Pharmaceutical Industries and Associations
Belgium



Ross McKinnon
Flinders University
Australia



Hiroshi Suzuki
University of Tokyo
Japan



Kathy Giacomini
University of San Francisco, California
USA



Pierre Meulien
Innovative Medicines Initiative
Belgium



Secretary of the International Scientific Programme Committee
Pieter Stolk
Exon Consultancy
The Netherlands

Strategic Advisors



Douwe Breimer
Leiden University
The Netherlands



Daan Crommelin
Utrecht University
The Netherlands



Henk de Jong
Advisor
France

Local Hospitality Committee



Karin Meyer
Chair, Swedish Pharmaceutical Society
Sweden



Anders Blanck
The Swedish Association of the Pharmaceutical Industry, LIF
Sweden



Anna Sandström
AstraZeneca
Sweden



Helena Tornberg
Swedish Pharmaceutical Society *Sweden*



Erik Björk
Upssala University
Sweden



Göran Alderborn
Uppsala University
Sweden



Per Artursson
Uppsala University
Sweden



Sven Frøkjær
University of Copenhagen
Denmark

COMMITTEES



Jouni Hirvonen
University of Helsinki
Finland



Arto Urtti
University of Helsinki
Finland



Henrik Schultz
University of Oslo
Norway

Young Scientist Comittee

University of Uppsala, Sweden



Caroline Alvebratt
Department of Pharmacy



Ilse Dubbelboer
Department of Pharmacy



Moustafa Ibrahim
Department of Pharmaceutical Biosciences



Rebecka Isaksson
Department of Medicinal Chemistry



Erik Melander
Department of Pharmaceutical Biosciences




Annelie Hansson
Department of Medicinal Chemistry


TABLE OF CONTENTS

Welcome	6
Committees	8
Tracks	12
Programme overview	14
Saturday 20 May	24
Sunday 21 May	27
Monday 22 May	29
Tuesday 23 May	37
Wednesday 24 May	51
Short communications	61
Short course	67
Meet the SIG meetings	70
Events	72
Exhibition	73
On site registration	74
Contact	75
Posters	76
List of participants	78

6 TRACKS

TRACK A	TRACK B	TRACK C	TRACK D	TRACK E	TRACK T
Drug Design, Fundamental & Translational Sciences	**Delivery & Targeting Sciences**	**Formulation, Manufacturing & QA**	**Regulatory Sciences**	**Science-based Practice**	**Thematic Symposia**





– What is the systems therapeutics approach and why is it important? –

Systems biology has emerged as a novel scientific discipline, which focuses on the analysis of biological networks as the basis for the functioning of biological systems. Systems analysis will revolutionize medicines and health research. This will impact on both the pharmaceutical sciences and pharmacy practice, says congress chairman Professor Meindert Danhof.

*In **research**, systems biology offers a novel approach to:*

i) Identifying pathways of disease;
ii) Discovering drug targets; and
iii) Discovering biomarkers *(for monitoring of the treatment response)*.

*In **practice**, this will lead to the introduction of 'systems therapeutics' interventions which are:*

i) Personalised *(both with respect to the selection of drug(s) and dosing regimens)*;
ii) Disease modifying *(with emphasis on pre-emptive and preventive treatments)*; and
iii) Complex *(such as multi-target drugs, rational drug-drug combinations, drug-device combinations)*.

TRACK **A**
Drug Design, Fundamental & Translational Sciences

Systems pharmacology focuses on the interfacing of pharmacology and systems biology. The development of novel biological models combined with the use of 'big data' will yield new insights in the mechanisms of disease. This enables scientists and clinicians to design novel drug treatments, aiming at modification of the disease process. In addition, novel 'systems pharmacology models' will cast further light on the pharmacokinetics and pharmacodynamics of candidate drugs. This allows the design of the most appropriate pre-clinical and clinical trials for toxicity and safety evaluations in pre-clinical studies, for the assessment of the tolerability in healthy volunteers and, last but not least, for the assessment of the efficacy in later clinical trials on patient groups.

TRACK **B**
Delivery & Targeting Sciences

Systems biology will increasingly yield new drugs which act at intracellular targets, or in tissues that are protected by specific barriers such as the brain. Moreover, it increasingly will yield new drug products that cannot be delivered orally. To overcome these barriers, insight in the cellular and subcellular disposition of drugs are indispensable. Novel imaging technologies constitute the basis for the study of the subcellular disposition of drug molecules. This will enable the development of new technologies for the delivery of complex molecules to their specific targets.

TRACK **C**
Formulation, Manufacturing & QA

A specific feature of novel systems therapeutic interventions is that they are 'personalized', both with respect to selection of the drug (or combination of drugs) and their dosage. New formulation and manufacturing technologies are required for the production of these drugs. The quality assurance of these 'precision treatments' is of paramount importance. The design of new diagnostic tools, monitoring devices and delivery systems is an integral part of this development.

TRACK **D**
Regulatory Sciences

Harnessing of 'big' information in regulatory science, the systems approach will allow advanced modelling and simulation that will be used to enhance product safety and to improve the prediction from clinical evaluations. We will be able to harness diverse data through information sciences to improve health outcomes.

TRACK **E**
Science-based Practice

The practice of science-based pharmacy will see major change. Individualised treatments will be a significant part of clinical practice and we will be able to use 'big data' for postmarketing drug evaluation. Systems therapeutics will trigger important discussions of the societal aspects of pre-emptive and preventive treatments.
Medicines research will be discussed against the background of four main themes related to future medicines for one world:
- Excellent Science
- Global Health
- Open Innovation
- Education & Training

TRACK **T**
Thematic Symposia

Keynote lectures, short communications and (special) symposia.

SATURDAY | MAY 20

The cutting edge in pharmaceutical sciences –
50 years of progress celebrating Les Benet's 80th birthday | ROOM K11

SUNDAY | MAY 21

TRACK **A**	TRACK **B**	TRACK **C**
Drug Design, Fundamental & Translational Sciences	**Delivery & Targeting Sciences**	**Formulation, Manufacturing & QA**

08:00 - 16:00

PSWC Young Scientist Satellite Conference day 2 / UPPSALA UNIVERSITY
'Improving your skills for research in drug discovery development and clinical usage'
(separate programme on the other side of this booklet)

SHORT COURSE
Drug transporters in ADME
ROOM K13

16:30 - 18:00

Plenary Opening Ceremony | VICTORIA HALL
'Future Medicines for One World'

18:00 - 19:00

Welcome reception | EXHIBITION HALL

08:30 - 17:45

08:00 - 18:00

TRACK **D**	TRACK **E**	TRACK **T**
Regulatory Sciences	**Science-based Practice**	**Thematic Symposia**

MONDAY MAY 22

TRACK A	TRACK B	TRACK C
Drug Design, Fundamental & Translational Sciences	**Delivery & Targeting Sciences**	**Formulation, Manufacturing & QA**

08:30 - 12:00

Plenary Opening Symposium | VICTORIA HALL
Systems approaches to drug discovery, development and clinical usage

12:00 - 13:30

Posters | EXHIBITION HALL

13:30 - 15:00

Short communications **A1** | ROOM K1

Short communications **A2** | ROOM K2

Short communications **B1** | ROOM K11

15:00 - 18:00

SYMPOSIUM **A1**
Systems pharmacology – towards the modeling of complex systems behaviour
ROOM K1

SYMPOSIUM **B1**
Towards understanding compound disposition at ever higher spatial resolution by label free methods
ROOM K2

SYMPOSIUM **C1**
Innovative production technologies for biologics
ROOM K11

19:00 - 20:30

Reception at Town Hall of Stockholm
CITY HALL / HANTVERKARGATAN 1 / 111 52 STOCKHOLM

08:30 - 20:30

TRACK D
Regulatory Sciences

TRACK E
Science-based Practice

TRACK T
Thematic Symposia

Short communications
B2 | ROOM A2

Short communications
C1 | ROOM A3

Short communications
E1 | ROOM K16

SYMPOSIUM **D1**
New approaches of regulating innovative medicines

ROOM A2

SYMPOSIUM **E1**
Precision medicine using genome-wide approaches: implementation to practice

ROOM A3

SYMPOSIUM **T1**
Integrated new therapeutics for global health – case studies from the Bill & Melinda Gates Foundation

ROOM K16

TUESDAY | MAY 23

TRACK A	TRACK B	TRACK C
Drug Design, Fundamental & Translational Sciences	**Delivery & Targeting Sciences**	**Formulation, Manufacturing & QA**

08:00 - 11:00

SYMPOSIUM A2
Systems pharmacology – modeling the contribution of transporters in drug disposition, response and toxicity
ROOM K1

SYMPOSIUM B2
Drug targeting: principles and products for precision medicine
ROOM K2

SYMPOSIUM C2
Continuous manufacturing – the 'holy grail' for pharmaceutical products?
ROOM K11

11:15 - 12:30

Short communications A3 | ROOM K1

Short communications B3 | ROOM K2

Short communications C2 | ROOM K11

12:30 - 14:00

Posters | EXHIBITION HALL

14:00 - 15:00

KEYNOTE LECTURE 1
Tissue-based protein profiles – implications for human biology, drug development and precision medicine
Matthias Uhlen /
Royal Institute of Technology, Sweden
ROOM K1

PRESENTATION IMS REPORT
Applying systems approaches to medicine use: outlook and considerations for patient care
Murray Aitkin /
Quintiles IMS Institute, USA
ROOM K2

KEYNOTE LECTURE 2
Education and training in the pharmaceutical sciences
William Charman /
Monash University, Australia
ROOM K11

08:00 - 15:00

TRACK D
Regulatory Sciences

TRACK E
Science-based Practice

TRACK T
Thematic Symposia

SYMPOSIUM D2
Data quality, robustness and relevance in pre-clinical research and development

ROOM A2

SYMPOSIUM E2
Impact of Pharmacy Practice Research on patient outcomes

ROOM A3

SYMPOSIUM T2
Putting open innovation into practice-case studies from Europe's Innovative Medicines Initiative

ROOM K16

Short communications D1 | ROOM A2

Short communications E2 | ROOM A3

Short communications T1 | ROOM K16

KEYNOTE LECTURE 3
Genomewide studies reveal transporters as determinants of drug action and toxicity

Kathy Giacomini /
UCSF, USA

ROOM A3

KEYNOTE LECTURE 4
Ensuring public healthcare quality through pharmacopeia standards and related programs

Ding Ming /
United States Pharmacopeial Convention (USP), USA

ROOM K16

TUESDAY MAY 23

TRACK A	TRACK B	TRACK C
Drug Design, Fundamental & Translational Sciences	**Delivery & Targeting Sciences**	**Formulation, Manufacturing & QA**

15:00 - 18:00

SYMPOSIUM A3
Systems approaches in drug discovery & design

ROOM K1

SYMPOSIUM B3
Lipid-based and lipid-associated drug delivery – how to make lipophilic targets orally attractable

ROOM K2

SYMPOSIUM C3
Manufacturing concepts for individualized therapies

ROOM K11

18:00 - 23:00

Banquet

SKANSEN / DJURGÅRDSLÄTTEN 49-51 / STOCKHOLM

15:00 - 18:00

TRACK D
Regulatory Sciences

SYMPOSIUM D3
Benefit-risk planning through the product life cycle

ROOM A2

TRACK E
Science-based Practice

SYMPOSIUM E3
Medicines for the real life population: the art of extrapolation

ROOM A3

TRACK T
Thematic Symposia

SYMPOSIUM T3
Education & training in pharmaceutical sciences

ROOM K16

WEDNESDAY | MAY 24

TRACK A	TRACK B	TRACK C
Drug Design, Fundamental & Translational Sciences	**Delivery & Targeting Sciences**	**Formulation, Manufacturing & QA**

08:00 - 09:00

KEYNOTE LECTURE 5

Use of 'Extended Clearance Concept' in New Drug Discovery and Developement; Application to a Drug Classification System and to a Design of Clinical Studies

Yuichi Sugiyama */ University of Tokyo, Japan*

ROOM K2

09:00 - 12:00

SYMPOSIUM A4

Systems Pharmacology – approaches to the assessment of drug safety

ROOM K1

SYMPOSIUM B4

Oral absorption of biopharmaceuticals: how to avoid GI degradation and reduce systemic elimination

ROOM K2

SYMPOSIUM C4

Responsible supply chains to assure global health

ROOM K11

13:30 - 15:00

Plenary Closing Session | VICTORIA HALL

'Future Medicines for One World'

08:00 - 15:00

TRACK D
Regulatory Sciences

TRACK E
Science-based Practice

TRACK T
Thematic Symposia

KEYNOTE LECTURE 6
Adherence, in drug development and usage' (in memory of John Urquhart)
***Bert Leufkens** / Utrecht University, The Netherlands*

ROOM A2

SYMPOSIUM D4
Non-biological complex drugs – similarity & interchangeability

ROOM A2

SYMPOSIUM E4
Big data, real world evidence and clinical practice

ROOM A3

SYMPOSIUM T4
Antimicrobial resistance: the battle we have to win

ROOM K16

SAT
20

SPECIAL **SYMPOSIUM**

ROOM K11

The Cutting Edge in Pharmaceutical Sciences – 50 Years of Progress Celebrating Les Benet's 80th Birthday



Following a decennial tradition, FIP is proud to sponsor this symposium celebrating the 50 Years of Progress in the Pharmaceutical Sciences in honor of the Chair of the first PSWC Congress, Professor Leslie Z. Benet.

As at Les Benet's 50th, 60th and 70.5 birthday symposia, leading scientists in our discipline will highlight the remarkable progress at the cutting edge of the science that we have observed over the past 50 years in our field. A celebratory banquet on Saturday evening will be held at the Scandic hotel.

CO-CHAIRS

Margareta Hammarlund-Udenaes /
Uppsala University, Sweden
Kathleen Giacomini /
University of San Francisco California, USA
Douwe Breimer /
Leiden University, The Netherlands

08:30 – 08:45
Symposium introduction
Douwe Breimer / Leiden University, Netherlands

08:45 – 09:15
Progress in drug administration technology and the future of medicine
Mitsuru Hashida / Kyoto University, Japan

09:15 – 09:45
What is happening inside: exploring gastrointestinal drug and formulation behavior
Patrick Augustijns / University of Leuven, Belgium

09:45 – 10:15
Model dependent and model independent approaches for the biopharmaceutic classification of drugs
Panos Macheras / University of Athens, Greece

10:15 – 10:45 COFFEE

10:45 – 10:50
Session Chairs Remarks

10:50 – 11:20
The role of PK in regulatory decision making – yesterday, today and the in future
Tomas Salmonson / Medical Products Agency, Sweden

11:20 – 11:50
New drug evaluation and approval in a model-based, Bayesian framework
Carl Peck / NDA Partners, USA

11:50 – 12:20
PK/PD as a source of innovative products delivering clinical value to patients
Suneel Gupta / IMPAX Laboratories, USA

SPECIAL **SYMPOSIUM**

ROOM K11

The Cutting Edge in Pharmaceutical Sciences – 50 Years of Progress Celebrating Les Benet's 80th Birthday

12:20 – 13:10 LUNCH

13:10 – 13:15
Session Chairs Remarks

13:15 – 13:45
The evolution of transporters in the SLC22 family
Kathleen Giacomini / University of California San Francisco, USA

13:45 – 14:15
Assessment of the effect of chronic kidney disease on CYP enzymes and transporters
Shiew-Mei Huang / Food and Drug Administration, USA

14:15 – 14:45
PK principles in target organs:
Intracellular unbound drug concentrations and blood-brain barrier transport. Development of concepts and methodology.
Margareta Hammarlund-Udenaes / Uppsala University, Sweden

14:45 – 15:15 COFFEE

15:15 – 15:20
Session Chair Remarks

15:20 – 15:50
Some reflections on pharmacokinetics
Malcolm Rowland / Manchester University, UK

15:50 – 16:20
Proposal of virtual clinical studies to examine the probability distribution of AUC at the target tissues; Application to irinotecan induced side effects
Yuichi Sugiyama / RIKEN Research Institute, Japan

16:20 – 16:50
To Repurpose or not Repurpose, or 'How much drug can I get to my target?' That is the question
Tudor Oprea / University of New Mexico, USA

16:50 – 17:20
Nonprofit drug development companies – A new paradigm
Victoria Hale / Medicines360, USA

17:20 – 17:30
Co-Chair Remarks

17:30 – 17:45
Les Benet Response

SUN
21

SUNDAY MAY 21 16:00 - 18:00

16:00 – 18:00 | VICTORIA HALL
Plenary Opening Ceremony

16:00 WELCOME BY:

Meindert Danhof /
Chair of PSWC, Netherlands

Carmen Peña /
President of FIP, Spain

Erem Bilensoy /
President of EUFEPS, Turkey

Karin Meyer /
Chair Local Hospitality Committee, Sweden

Awards

16.40
Introduction to the theme
'Future Medicines for One World'

16.45
Medicines for One World through global collaboration and harmonization
Dan Hartman /
Bill & Melinda Gates Foundation, USA

17.05
Impacts of artificial intelligence for pharmaceutical industry: Disruptive innovations in scientific discovery and biomedical sciences
Hiroaki Kitano /
Systems Biology Institute, Japan

17.25
Open Innovation – Strengthening research, enhancing transparency & attaining public support
Pierre Meulien /
Innovative Medicines Initiative, Belgium

16.30 ENTERTAINMENT – THE VISITORS

17.45 ENTERTAINMENT – THE VISITORS

MON
22

MONDAY MAY 22 08:30 - 12:00

08:30 - 12:00 I VICTORIA HALL
Plenary Opening Symposium

CO-CHAIRS
Hiroshi Suzuki / Japan
Kathy Giacomini / USA

08:30 – 08:40
Introductory remarks
Hiroshi Suzuki / University of Tokyo, Japan

08:40 – 09:10
The innovative pipelines of the pharmaceutical industry
Thomas Allvin / EFPIA, Sweden

09:10 – 09:40
Future medicines: drug delivery & targeting sciences
Kazunori Kataoka / University of Tokyo, Japan

09:40 – 10:10
Future medicines: formulation, manufacturing and quality assurance
Jukka Rantanen / University of Copenhagen, Denmark

10:10 – 10:40 BREAK

10:40 – 11:10
Future medicines: regulatory sciences
Tomas Salmonson / MPA, Uppsala Sweden & EMA, London

11:10 – 11:40
The science of precision medicine and its translation to the clinic
William Evans / St Jude's Children Research Hospital, USA

11:40 – 12:00
Concluding remarks
Kathy Giacomini / UCSF, USA

12:00 – 13:30
Posters

13:30 – 14:45
Short communications different tracks

MONDAY MAY 22 15:00 - 18:00

A1 I ROOM K1

The emerging discipline of Quantitative Systems Pharmacology (QSP): combining PKPD and Systems Biology

This session brings together a world-class group of scientists who will give a range of presentations that focus on the interfacing of quantitative systems pharmacology (QSP) and Systems Biology (SB) with the aim to understand the interactions between drug action and disease processes. QSP constitutes the scientific basis for the design of novel disease treatments which modify the disease process.

CO-CHAIRS
Piet van der Graaf / The Netherlands
Don Mager / USA

15:00 – 15:15
The emerging discipline of Quantitative Systems Pharmacology (QSP): combining PKPD and Systems Biology
Piet van der Graaf / Leiden University, The Netherlands

15:15 – 15:50
Quantitative systems pharmacology in oncology
Don Mager / University at Buffalo, USA

15:50 – 16:25
Quantitative systems pharmacology in infectious diseases
Jeremie Guedj / INSERM, France

16:25- 16:45 BREAK

16:45- 17:20
Quantitative systems toxicology
Hiroshi Suzuki / Tokyo University, Japan

17:25 – 17:55
Systems medicine in rheumatoid arthritis
Tim Radstake / UMC Utrecht, The Netherlands

17:55 – 18:00
Concluding remarks

MONDAY MAY 22 15:00 - 18:00

B1 | ROOM K2

Towards understanding compound disposition at ever higher spatial resolution by label free methods

Dedicated to the memory of:
Professor Tsutomu Masujima (1949 – 2017)
A truly pioneering scientist who strove to do what others could not do.

All too frequently we do not know enough about the likely disposition of compounds early in the discovery phase with the result that there is a greater emphasis placed on potency at the target which is more easily optimised. This session will focus on contemporary methods for increasing the understanding of cellular and subcellular compound disposition using unlabelled drugs, suitable for use in the lead optimisation phase.

CO-CHAIRS
Mike Hann / UK
Paulina Rakowska / UK

15:05 – 15:35
Intracellular unbound drug concentrations: methodology and application for understanding cellular drug exposure
André Mateus / University of Uppsala, Sweden

15:35 – 16:05
A modular probe strategy for drug localization, target identification and target occupancy measurement on single cell level
Anna Rutkoswka-Klute / Cellzome, Germany

16:05 – 16:35
3D label-free imaging of drug uptake into cells and bacteria using secondary ion mass spectrometry
Paulina Rakowska / National Physical Laboratory, UK

16:35 – 16:50 BREAK

16:50 – 17:20
Utilizing label free high content imaging methods to span the gap from discovery to the clinic
Zane Arp / GSK, USA

17:20 – 17:50
Single-cell drug discovery, diagnosis and personalized medicine by live-MS
Ahmed Ali / RIKEN Quantitative Biology Center, Japan

17:50 – 18:00
Concluding remarks

MONDAY MAY 22 15:00 - 18:00

C1 | ROOM K11
Innovative production technologies for biologics

The need for high quality biologic drugs, including biosimilars, is fueling innovation in biopharmaceutical manufacturing technologies. This symposium outlines opportunities and challenges associated with new technologies such as single-use bioreactors, continuous purification processing, and real-time quality analysis that have been effectively explored to enable fast scale-up of high-quality complex products. Furthermore, experts will delineate important adaptations in quality risk management that are necessary to assure safety of biologics when employing innovative production technologies.

CHAIR
Hanns-Christian Mahler / Switzerland

15:00 – 15:35
Innovation in biologics drug product development & manufacture
Hanns-Christian Mahler / Lonza, Switzerland

15:35 – 16:10
Quality risk management in the manufacture of biologics
Akhiko Hirose / National Institute of Health Sciences, Japan

16:10 – 16:30 BREAK

16:30 – 17:05
Control strategies for surfactants in biopharmaceuticals
Atanas Koulov / Lonza, Switzerland

17:05 – 17:40
Assessing the impact of manufacturing processes on drug product composition and stability
Mark Bolgar / Bristol Myers Squibb, USA

17:40 – 18:00
Panel discussion
Hanns-Christian Mahler / Lonza, Switzerland

MONDAY MAY 22 15:00 - 18:00

D1 | ROOM A2

New approaches of regulating innovative medicines

Throughout the world, regulators are exploring new ways to provide access to patients for innovative medicines that address urgent medical needs at the earliest moment, while assuring appropriate controls for quality, safety and efficacy. In this session we will assess current approaches in different regulatory systems, explore commonalities and identifies lessons for the future.

CHAIR
Alasdair Breckenridge / UK

15:00 – 15:10
Opening remarks
Alasdair Breckenridge / University of Liverpool, UK

15:10 – 15:45
To Adapt or not to Adapt
Hans-Georg Eichler / European Medicines Agency, UK

15:45 – 16:20
Exploring innovative regulatory pathways: A US perspective
Larry Liberti / Centre for Innovation in Regulatory Science (CIRS), USA

16:20 – 16:40 BREAK

16:40 – 17:15
Industry perspectives on regulating innovative medicines
Joseph Scheeren / Bayer, Switzerland

17:15 – 17:50
PMDA's contribution to innovative medicines
Toshiyoshi Tominaga / PMDA, Japan

17:50 – 18:00
Concluding remarks

MONDAY MAY 22 15:00 - 18:00

E1 | ROOM A3

Clinical implementation of precision medicine: from genomewide discovery to practice

With recent initiatives in the USA and indeed globally, precision medicine represents a new discipline specifically focused on the translation of genomic discoveries to patient care. However for precision medicine to become a reality major challenges must be addressed. First and foremost, large cohorts of patients with available biological samples and electronic health information are needed to make robust discoveries that can be effectively translated to patient care. Importantly, expert advice on the use of genomic information to guide drug selection and dosing in the context of individual patients from diverse ethnic and racial backgrounds is needed.
This symposium will focus on key issues for implementation of precision medicine in patient practice. Large clinical consortia with electronic health information will be described. Issues relevant to translation of new discoveries will be highlighted, particularly, the use of genetic information to guide the selection of safe and effective therapies.

CO-CHAIRS
Kathy Giacomini / USA
Jesse Swen / The Netherlands

15:00 – 15:10
Genomewide approaches to the clinical implementation of precision treatments in clinical practice – Opening remarks
Kathy Giacomini / University of California, USA

15:10 – 15:45
Pharmacogenetics in Europe: The European Pharmacogenetics Implementation Consortium Initiative
Ron van Schaik / Erasmus MC, The Netherlands

15:45 – 16:20
The japan biobank and the PGRN-RIKEN collaboration: facilitating new discoveries in precision medicine
Michaki Kubo / Center for Integrative Medical Sciences, RIKEN, Japan

16:20 – 16:40 BREAK

16:40 – 17:15
The Clinical Pharmacogenetics Implementation Consortium: leading translation of precision medicine
Mary Relling / St. Jude's Children's Research Hospital, USA

17:15 – 17:50
Genomewide approaches to discovering drug safety biomarkers
Munir Pirmohamed / University of Liverpool, UK

17:50 – 18:00
Concluding remarks
Jesse Swen / Leiden University Medical Center, The Netherlands

MONDAY MAY 22 15:00 - 18:00

T1 | ROOM K16
Integrated development of new therapeutics for global health

CHAIR
Dan Hartman / USA

15:00 – 15:10
General introduction: integrated development of new therapeutics for global health
Dan Hartman / Bill & Melinda Gates Foundation, USA

15:10 – 15:45
Accelerators: Creating collaborative networks to advance drug discovery for tuberculosis
Peter Warner / Bill & Melinda Gates Foundation, USA

15:45 – 16:20
Formulators: bringing new technologies forward in drug formulation to address global health needs
Susan Herschensen / Bill & Melinda Gates Foundation, USA

16:20 – 16:40 BREAK

16:40 – 17:15
Quantitators: Using model based drug development to effectively develop anti-malarial agents
Steve Kern / Bill & Melinda Gates Foundation, USA

17:15 – 17:50
Regulators: Optimizing and aligning regulatory systems to help bring quality medicines to global health needs
Murray Lumpkin / Bill & Melinda Gates Foundation, USA

17:50 – 18:00
Concluding remarks: integrated development of new therapeutics for global health
Dan Hartman / Bill & Melinda Gates Foundation, USA

TUE
23

TUESDAY MAY 23 08:00 - 11:00

A2 | ROOM K1

Systems approaches to modeling the contribution of transporters in drug disposition, response and toxicity

This session brings together a world-class group of scientists who will give a range of presentations that focus on experimental and computational models to understand the role of drug transporters in drug toxicity and response with a particular focus on the blood brain barrier.

CO-CHAIRS
Mikko Niemi / Finland
Rada Savic / USA

08:00 – 08:10
Systems approaches to modeling the contribution of transporters in drug disposition, response and toxicity – general introduction
Mikko Niemi / University of Helsinki, Finland

08:10 – 08:45
Quantifying the impact of transporters on cellular drug permeability
Per Artursson / University of Uppsala, Sweden

08:45 – 09:20
Modeling and prediction of the effect of transporters on differences of unbound drug concentrations between the plasma, brain and cerebrospinal fluid
Yuichi Sugiyama / University of Tokyo, Japan

09:20- 09:40 BREAK

09:40 – 10:15
Uptake of cocaine, opioids, and other organic cations at the BBB
Jean-Michel Scherrmann / Paris Descartes University, France

10:15 – 10:50
Organic action uptake of GHB at the BBB: incorporation of brain transport in modeling of PK/PD
Marilyn Morris / University at Buffalo, USA

10:50 – 11:00
Systems approaches to modeling the contribution of transporters in drug disposition, response and toxicity – concluding remarks
Rada Savic / University of California, USA

TUESDAY MAY 23 08:00 - 11:00

B2 | ROOM K2

Drug targeting: principles and products for precision medicine

Many drug delivery systems and drug targeting strategies have been evaluated over the years. In this session, recent advances in the use of targeted (nano-) therapeutics for improving the treatment of cancer, cardiovascular disease and inflammatory disorders will be presented. In this context, both fundamental insights into biological and pathophysiological mechanisms, as well as progress towards pharmaceutical production and clinical translation will be addressed.

CHAIR
Twan Lammers / Germany

08:00 – 08:10
Introductory remarks
Twan Lammers / RWTH Aachen University Clinic, Germany

08:10 – 08:45
Drug targeting to tumors: Concepts and barriers vs. ever more nanocarriers
Twan Lammers / RWTH Aachen University Clinic, Germany

08:45 – 09:20
Harnessing RNA nanomedicine for precision therapy in cancer and inflammation
Dan Peer / Tel Aviv University, Israel

09:20 – 09:40 BREAK

09:40 – 10:15
Drug targeting and imaging in cardiovascular disease
Willem Mulder / Mount Sinai School of Medicine, USA

10:10 – 10:50
Bioresponsive polymeric nanomedicines for tumor targeting
Zhiyuan Zhong / Soochow University, China

10:50 – 11:00
Concluding remarks
Twan Lammers / RWTH Aachen University Clinic, Germany

TUESDAY MAY 23 08:00 - 11:00

C2 | ROOM K11

Continuous manufacturing – the 'holy grail' for pharmaceutical products?

As conventional large batch manufacturing is increasingly regarded as inflexible and unsustainable, the continuous manufacturing concept has planted a new hope in the pharmaceutical industry to improve process efficiency and product quality. This session will highlight the various elements necessary for successful implementation of continuous manufacturing predicted to resulting in reduced production time and a shorter time to market.

CHAIR
Paul Wan Sia Heng / Singapore

08:00 – 08:35
Continuous manufacturing: the future in pharmaceutical solid dosage form manufacturing
Paul Wan Sia Heng / National University of Singapore, Singapore

08:35 – 09:10
Making the business case for continuous manufacturing in the pharmaceutical industry
Tomás Harrington / University of Cambridge, UK

09:10 – 09:30 BREAK

09:30 – 10:05
Developing the end-to-end supply chain
Craig Johnston / University of Strathclyde, UK

10:05 – 10:40
On-demand continuous-flow production of pharmaceuticals in a compact, reconfigurable system
Andrea Adamo / MIT, USA

10:40 – 11:00
Panel discussion
Paul Wan Sia Heng / National University of Singapore, Singapore

TUESDAY MAY 23 08:00 - 11:00

D2 | ROOM A2

Data quality, robustness and relevance in pre-clinical research and development

Reproducibility and relevance of research findings represent the pillars of the scientific method. For drug discovery and preclinical drug development, as well as basic science, robust data and scientific rigor are key drivers for decision making, determining the validity of hypotheses, patent strength, time-to-market and consequently knowledge gain and availability of new treatments to patients. In this symposium we will highlight the pertinent issues and provide an overview of some of the initiatives that aim to address those issues, including strategies followed by pharmaceutical industry, academia, funding agencies and publishers, and introduce some of the more recent consorted approaches.

CO-CHAIRS
Magda Chlebus / Belgium
Thomas Steckler / Belgium

08:00 – 08:10
Introductory remarks
Thomas Steckler / Janssen Research & Development, Belgium

08:10 – 08:45
Non-regulated preclinical data quality, reproducibility and robustness of data: what can we learn from the regulatory perspective?
Beatriz Lima / University of Lisbon, Portugal

08:45 – 09:20
Reproducibility, reliability and sharing of biomedical data – a publishers perspective
Iain Hrynaszkiewicz / HSS Publishing, Open Research, Nature/Springer, UK

09:20 – 09:40 BREAK

09:40 – 10:15
Improving research quality in academic settings using quality assurance best practices
Rebecca Davies / University of Minnesota, USA

10:15 – 10:5
IMI consortium on data quality in preclinical research and development – an industrial perspective
Thomas Steckler / Janssen R&D, Belgium

10:50 – 11:00
Concluding remarks
Magda Chlebus / European Federation of Pharmaceutical Industries and Associations, Belgium

TUESDAY MAY 23 08:00 - 11:00

E2 I ROOM A3

Impact of Pharmacy Practice Research on patient outcomes

This session will provide delegates with a deep understanding of the impact on patients and systems using high quality research design and methodologies in the areas of medication review, medication adherence, and cardiovascular risk reduction and pharmacotherapy.

CO-CHAIRS

Martin Schulz / Germany
Charlie Benrimoj / Australia

08:00 – 08:10
Impact of Pharmacy Practice Research on patient outcomes – introductory remarks
Charlie Benrimoj / University of Technology Sydney, Australia

08:10 – 08:45
Characterization of published RCTs assessing clinical pharmacy services around the world
Fernando Fernandez-Llimos / University of Lisbon, Portugal

08:45 – 09:20
Improving medication adherence – improving outcomes
Martin Schulz / Freie Universitaet Berlin, Germany

09:20 – 09:40 BREAK

09:40 – 10:15
Pharmacist-led home medicines review and residential medication
Timothy Chen / University of Sydney, Australia

10:15 – 10:50
Improving outcomes by pharmacists' intervention in cardiovascular diseases
Ross Tsuyuki / University of Alberta, Canada

10:50 – 11:00
Impact of Pharmacy Practice Research on patient outcomes – concluding remarks
Martin Schulz / Freie Universitaet Berlin, Germany

TUESDAY MAY 23 08:00 - 11:00

T2 I ROOM K16

Putting open innovation into practice – case studies from Europe's Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) was established in 2008 as a partnership between the European Union and the European pharmaceutical industry. IMI is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating open innovation among the key players involved in healthcare research, including universities, pharmaceutical companies, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.

CHAIR
Pierre Meulien / Belgium

08:00 – 08:10
Putting open innovation into practice – introductory remarks
Pierre Meulien / Innovative Medicines Initiative, Belgium

08:10 – 08:35
The eTOX project: pooling legacy data to advance safety sciences
Ferran Sanz / Pompeu Fabra University , Spain

08:45 - 09:10
Open PHACTS – lessons learned in pioneering semantic technology for drug discovery
Barend Mons / Leiden University Medical Center, The Netherlands

09:10 – 09:30 BREAK

09:30 – 09:55
The European Lead Factory – making a pan-European compound collection & screening centre a reality
Dimitrios Tzalis / Taros Chemicals, Germany

09:55 – 10:20
The ENABLE project: an antibiotic discovery platform
Anders Karlén / Uppsala University, Sweden

10:20 – 10:45
The ULTRA-DD project: delivering new tools and resources to speed up
Michael Sundstrom / Karolinska Institute, Sweden

10:45 – 11:00
Putting open innovation into practice – concluding remarks
Pierre Meulien / Innovative Medicines Initiative, Belgium

TUESDAY | MAY 23 14:00 - 15:00

14:00 - 15:00
Keynote Lectures

KEYNOTE LECTURE 1 | ROOM K1

Tissue-based protein profiles – implications for human biology, drug development and precision medicine

Matthias Uhlen /
Royal Institute of Technology, Sweden
–
CO-CHAIR
Eva Goebgen /
Institute for Pharmacy, Germany

KEYNOTE LECTURE 2 | ROOM K11

Education & training in the pharmaceutical sciences

William Charman /
Monash University, Australia
–
CO-CHAIR
Tahnee Dening /
University of South Australia, Australia

KEYNOTE LECTURE 3 | ROOM A3

Genomewide studies reveal transporters as determinants of drug action and toxicity

Kathy Giacomini /
UCSF, USA
–
CO-CHAIR
Francis Williams Ojara /
Freie Universität Berlin, Germany

KEYNOTE LECTURE 4 | ROOM K16

Ensuring public healthcare quality through pharmacopeia standards and related programs

Ding Ming /
United States Pharmacopeial Convention (USP), USA
–
CO-CHAIR
Tamara Gómez Dacoba /
University of Santiago de Compostela, Spain

TUESDAY MAY 23 15:00 - 18:00

A3 | ROOM K1
Systems approaches to drug discovery and design

Progress human genetics, cellular and systems biology has a major impact in the field of drug discovery and design. Important developments in this area are: the emergence of Electro Localization Function (ELF) chemistry as a new approach to the design and synthesis of novel biologically active substances, phenotypic screening to the selection of novel drug candidates, and systems approaches to the identification of novel drug targets in biological networks. This symposium discusses these developments and their application, in particular also in the context of the design of novel anti-microbial agents.

CHAIR
Ton Rijnders / The Netherlands

15:00 – 15:10
Introductory remarks
Ton Rijnders / Lygature, The Netherlands

15:10 – 15:45
Chemical approaches to support lead discovery *(including within the European Lead Factory)*
Adam Nelson / Leeds University, UK

15:45 – 16:20
Metabolimics and 'organ on a chip' technology as novel approaches in drug discovery and development in research
Thomas Hankemeier / Leiden Academic Centre of Drug Research, The Netherlands

16:20 – 16:40 BREAK

16:40 – 17:15
Catalizing translation through new paradigms in early drug discovery
Anton Simeonov / National Institutes of Health, USA

17:15 – 17:50
Tackling anti-microbial resistance, development of novel metallo-ß-lactamase inhibitors
Jurgen Brem / University of Oxford, UK

17:50 – 18:00
Concluding remarks
Ton Rijnders / Lygature, The Netherlands

TUESDAY MAY 23 15:00 - 18:00

B3 | ROOM K2

Lipid-based and lipid-associated drug delivery – how to make lipophilic targets orally attractable

The number of poorly water-soluble drugs is increasing and partly this has been attributed to the high lipophilicity of the drugs. The increase in lipophilicity has been related to organizational factors and poor medicinal chemistry approaches, but it is clear that to some extent the lipophilicity is also driven by the molecular requirements of the target. In other cases it may be driven by the target sitting intracellularly, meaning that the compound must be lipophilic enough to traverse cellular membranes. In this session we will address a wide range of questions related to lipid-based, or lipid-associated (food driven) drug delivery. A panel of speakers, all with an update view of the science behind making use of the 'lipidic' strategy to enable efficient and reproducible oral drug delivery, has been put together for the session. All speakers have been confirmed. The session will highlight new insights into the interplay between natural lipids and lipids used in dosage forms, the interplay between the intestinal wall and such lipids, and increase the awareness of making use of medicinal chemistry to better match compounds with lipid-based formulation strategies via transiently increasing the lipophilicity of compounds. The chairs of the session will make sure that the overlap between these talks are minimized by active communicating with the invited speakers and facilitate sharing slides between the speakers before the meeting takes place.

CO-CHAIRS
Christel Bergström / Sweden
Christopher Porter / Australia

15:00 – 15:10
Lipid-based and lipid associated drug delivery – introductory remarks
Christopher Porter / Monash University, Australia

15:10 – 15:45
Effect of dietary lipids on drug dissolution and permeation
Rebecca Carrier / Northeastern University, USA

15:45 – 16:20
Dissolution/release and permeation – impact of bile
Shinji Yamashita / Setsunan University, Japan

16:20 – 16:40 BREAK

16:40 – 17:15
Lipid-based formulations; solubilizing and supersaturating systems with complex interplay with cell membranes
Vincent Jannin / Gattefossé, France

17:15 – 17:50
Lipophilic conjugates and complexes to promote drug integration into lipid absorption pathways
Christopher Porter / Monash University, Australia

17:50 – 18:00
Lipid-based and lipid associated drug delivery – concluding remarks
Christel Bergström / Uppsala University, Sweden

TUESDAY MAY 23 15:00 - 18:00

C3 | ROOM K11
Manufacturing concepts for individualised therapies

Recent breakthroughs in diagnostics, including genotyping and biomarkers, have paved the way towards implementation of 'precision medicine' intended to meet the therapeutic needs of each individual patient. To fully achieve societal benefits of individualised therapies, conventional manufacturing platforms must be adapted for mass customization. This session will focus on the challenges and opportunities associated with enabling future mass customized formulation and manufacturing technologies needed for precision pharmaceutics.

CHAIR
Staffan Folestad / Sweden

15:00 – 15:35
Introduction to manufacturing concepts for individualized therapies – where are we in pharma
Staffan Folestad / AstraZeneca, Sweden

15:35 – 16:10
Additive manufacturing of individualised medicines
Niklas Sandler / Åbo Akademi University, Finland

16:10 – 16:30 BREAK

16:30 – 17:05
Nano-engineered drug delivery for individualised therapies
Maria José Alonso / University of Santiago de Compostela, Spain

17:05 – 17:40
Innovative developments in patient centric formulations
Alvaro Goyanes / UCL, UK

17:40 – 18:00
Panel discussion focusing on 'Manufacturing concepts for individualised therapies – where could pharma be?'
Staffan Folestad / AstraZeneca, Sweden

TUESDAY MAY 23 15:00 - 18:00

D3 | ROOM A2

Benefit-risk planning through the product life cycle

A benefit risk-assessment of a medicine is not a single assessment that takes place during one moment in time. Rather, benefit-risk assessments take place throughout the product life cycle and can be update regularly. Also, the nature of the tools and methods available is dynamic: from early stage drug development until the late post-marketing phase. This session will be exploring cutting-edge approaches in this area.

CHAIR
Rogerio Gaspar / Portugal

15:00 – 15:10
Opening remarks by the chair

15:10 – 15:45
Standards of evidence for regulatory decision making
***Rob Hemmings** / EMA/MHRA, USA*

15:45 – 16:20
Building substantial evidence never ends
***Carl Peck** / UCSF, USA*

16:20 – 16:40 BREAK

16:40 – 17:15
Industry perspective on life-cycle management
***Jens Heisterberg** / Novo Nordisk, Denmark*

17:15 – 17:50
To be announced

17:50 – 18:00
Concluding remarks
***Rogerio Gaspar** / University of Lisbon, Portugal*

TUESDAY MAY 23 15:00 - 18:00

E3 | ROOM A3

Medicines for the real life population: the science of extrapolation

In drug research and in clinical practice frequently situations arise in which no information on the optimal dose is available in a relevant group of patients. Examples of such situations include the selection of the dose in phase 1 clinical trials in healthy subjects and the selection of the dosage in special patients groups such as neonates, children, or patients with obesity. This symposium addresses the scientific basis of extrapolation focusing on a diversity of in vivo and in vitro approaches, including allometric scaling and physiology-based pharmacokinetic-pharmacodynamic modelling.

CHAIR
Douwe Breimer / The Netherlands

15:00 – 15:05
The science of extrapolation – Introductory remarks
Douwe Breimer / *LACDR, Leiden University, The Netherlands*

15:05 – 15:35
The science of extrapolation: in vitro and in vivo approaches
Amin Rostami / *University of Manchester, UK*

15:35 – 16:05
Dose selection in phase 1 clinical trials in oncology
Jan Schellens / *Netherlands Cancer Institute, The Netherlands*

16:05 – 16:25 BREAK

16:25 – 16:50
PBPK modelling and simulation in pediatric drug development
Andrea Edginton / *University of Waterloo, Canada*

16:50 – 17:15
Dose selection in obesity: effect of variation in size and function
Catherijne Knibbe / *St. Antonius Hospital Nieuwegein, The Netherlands & LACDR, Leiden University, The Netherlands*

17:15 – 17:40
Towards precision treatment: the impact of systems pharmacology
Hiroshi Suzuki / *University of Tokyo, Japan*

17:40 – 18:00
The science of extrapolation – panel discussion
Douwe Breimer / *LACDR, Leiden University, The Netherlands*

TUESDAY MAY 23 15:00 - 18:00

T3 | ROOM K16
Education & training of the future pharmaceutical sciences workforce

Development of novel medicines capable of more effectively reducing disease burden across the globe challenges existing paradigms of pharmaceutical sciences education and training. As a global organization, FIP is dedicated to share best practices in contemporary pharmaceutical sciences education and training among different countries. This session will outline the opportunities for academia and industry working jointly on innovative training programs to foster a competent pharmaceutical sciences workforce that is ready to tackle the challenges of the future. In addition to presentations from pharmaceutical sciences educators and employers, this session features viewpoints from young pharmaceutical scientists (i.e., graduate students, postdocs, new employees) and a moderated interactive panel discussion engaging the members of the audience with speakers.

CO-CHAIRS
Ross McKinnon / Australia
Giovanni Pauletti / USA

15:00 – 15:20
Opportunities for the future pharmaceutical sciences workforce
Giovanni Pauletti / FIP, USA

15:20 – 16:10
Attracting the best students into a pharmaceutical sciences career
Case studies of young pharmaceutical scientists from different geographical regions who entered PharmSci from non-traditional background
Kathryn Browning / Uppsala University, Sweden
Sifei Han / Monash University, Australia
Chad Pickens / The University of Kansas, USA

16:10 – 16:30 BREAK

16:30 – 16:50
Tomorrow's pharmaceutical sciences workforce – employer perspective
Brian Henry /
Pfizer Worldwide Research and Development, UK

16:50 – 17:10
Innovative models of PhD training
Ross McKinnon / Flinders University, Australia

17:10 – 18:00
Panel discussion
Ross McKinnon and Giovanni Pauletti

WED
24

WEDNESDAY MAY 24 08:00 - 09:00

08:00 - 09:00
Keynote Lectures

KEYNOTE LECTURE 5 | ROOM K2

Use of 'Extended Clearance Concept' in new drug discovery and developement; application to a drug classification system and to a design of clinical studies

Yuichi Sugiyama /
University of Tokyo, Japan
–
CO-CHAIR
Annika Kyssä /
Astra Zeneca, Sweden

KEYNOTE LECTURE 6 | ROOM A2

Adherence, in drug development and usage *(in memory of John Urquhart)*

Bert Leufkens /
Utrecht University, The Netherlands
–
CO-CHAIR
Jay Gopal Meher /
India

WEDNESDAY MAY 24 09:00 - 12:00

A4 | ROOM K1

Systems pharmacology – innovative approaches to drug safety

This session will discuss: how *i)* drug safety predictions based on pre-clinical studies can be exploited to inform clinical safety predictions; *ii)* information from post-marketing adverse event databanks can be utilized to inform drug safety; *iii)* systems pharmacology approaches can complement big data analysis to understand the underlying molecular and mechanistic causes of adverse events for hypothesis generation and novel safety predictions.
Promoted jointly by the AAPS Systems Pharmacology Focus Group, ASCPT Systems Pharmacology Community, ISPE International Society of Pharmacoepidemiology, FIP SIG on PK/PD and Systems Pharmacology, ISoP Special Interest Group on Quantitative Systems Pharmacology, and the UK QSP Network

CO-CHAIRS
Mirjam Trame / USA
Masanobu Sato / Japan

09:00 – 09:05
Introductory remarks
Mirjam Trame / University of Florida, USA

09:10 – 09.35
Regulatory perspective on drug safety assessment during drug development
Masanobu Sato / Pharmaceuticals and Medical Devices Agency (PMDA), Japan

09:35 – 10:00
Application of systems pharmacology modeling to explore safety issues arising at different stages of drug development
Oleg Demin / ISB Moscow, Russia

10:00 – 10:25
Translating preclinical safety signals to the clinic to inform compound discovery and early development
Jay Mettetal / AstraZeneca, USA

10:25 – 10:40 BREAK

10:40 – 11:05
Systems pharmacology models to assess immunogenicity
Paolo Vicini / MedImmune, UK

11:05 – 11:30
Integration of mechanistic information generated through systems pharmacology into pharmacoepidemiologic studies aimed at making inferences about the real-life impact of emerging safety concerns
Almut Winterstein / University of Florida, USA

11:30 – 11:55
Patient data driven strategies in drug safety assessment
David Jackson / Molecular Health, Germany

11:55 – 12:00
Concluding remarks
Mirjam Trame / University of Florida, USA

WEDNESDAY MAY 24 09:00 - 12:00

B4 | ROOM K2
Oral absorption of biopharmaceuticals revisited

Oral administration is the preferred route of administration for drugs but this route has not been feasible for biopharmaceuticals due very poor absorption due to the large molecular weight, hydrophilic nature and instability to enzymatic degradation in the gastro-intestinal (GI) tract. Attempts have therefore been made for more than 30 years to develop drug delivery systems allowing to overcome these obstacles and make oral products possible. Unfortunately, the outcome has been disappointing and today there are still no oral biopharmaceutical drug delivery based products for systemic treatment on the market. However, there is a currently a renewed research interest in this challenging field. One of the factors that changed the game is chemistry progress providing stable modifications thereby both avoiding GI degradation as well as generating very slow systemic elimination. The latter aspect is important from a drug delivery perspective since the fluctuations in plasma concentrations will be less sensitive to variations in extent of absorption at steady state. Thus, this re-opens interest for delivery approaches that enhances oral absorption of such drugs. Today this approach not only includes peptides but also small oligonucleotides further boosting interest. The current session will give a timely update of recent advances in this field and stimulate a discussion of remain critical questions and next steps.

CO-CHAIRS
Hans Lennernäs / Sweden
Bertil Abrahamsson / Sweden

09:00 – 09:10
Introductory remarks
Hans Lennernäs / Uppsala University, Sweden

09:10 – 09:45
Conjugation breakthrough technologies
Istvan Toth / The University of Queensland, Australia

09:45 – 10:20
Recent progress in formulation approaches
David Brayden / University College Dublin, Ireland

10:20- 10:40 BREAK

10:40 – 11:15
Biopharmaceutics prerequisites with emphasis on intestinal stability
Randy Mrsny / University of Bath, UK

11:15 – 11:50
Oral absorption of peptides/oligonucleotides – how far have we come?
David Brayden / University College Dublin, Ireland

11:50 – 12:00
Concluding remarks
Bertil Abrahamsson / AstraZeneca, Sweden

WEDNESDAY MAY 24 09:00 - 12:00

C4 | ROOM K11

Responsible supply chains to assure global health

Access to medicines in many countries, especially for the poor and underprivileged, remains less than optimal. FIP is committed to identify barriers limiting adequate supply and availability of essential medicines for patients and jointly work with governments and local professional organization to strive for improved access to safe and effective medicines for their populations. This session aims to raise awareness among the pharmaceutical sciences community how fragile medicine supply chains across the globe can be. In addition, experts will debate the impact of pharmaceutical development on the environment and how this may factor into the social responsibility of enhancing access to medicines.

CHAIR
Takuya Kumamoto / Japan

09:00 – 09:35
Environmental impact of drug manufacturing
Takuya Kumamoto / Musashino University, Japan

09:35 – 10:10
Pharmaceuticals in surface and ground water: Case in Nigeria
Chimezie Anyakora / University of Lagos, Nigeria

10:10 – 10:30 BREAK

10:30 – 11:05
How robust are the global pharmaceutical supply chains?
David Gonsalvez / Malaysia Institute for Supply Chain Innovation (MISI), Malaysia

11:05 – 11:40
Bioeconomy – How to build human resource capacity in scientific research
Ahmed Fahmi / UNESCO, France

11:40 – 12:00
Panel discussion
Takuya Kumamoto / Musashino University, Japan

WEDNESDAY MAY 24 09:00 - 12:00

D4 | ROOM A2
Non-Biological-Complex-Drugs

The rise of bio- and nano-technology has accelerated the development of complex drugs, a class of products that include – but are not limited to – Biological and Non Biological Complex Drug (NBCD) products such as iron-carbohydrate complexes, glatiramoids, polymeric micelles, emulsions, liposomes and other products in the class of nanomedicines. While guidance for developing generic versions of small molecule drugs is well-established and guiding principles for biosimilars and some follow-on versions of NBCDs are evolving, the regulatory science debate is still going on and many basic questions are left. Moreover, alignment of science based international approaches to the approval of these complex drug products and their follow on versions would be highly desired for those companies that develop follow-on versions. At the moment, this alignment of the legal frameworks is still 'under construction', at best.

CO-CHAIRS

Stefan Mühlebach / Switzerland
Daan Crommelin / The Netherlands

09:00 – 09:10
Introductory remarks
Stefan Mühlebach / University of Basel, Switzerland
& Daan Crommelin / Utrecht University, The Netherlands

09:10 – 09:45
Nanomedicines: complex in nature and a challenge for innovator and regulator
Gerrit Borchard / University of Geneva, Switzerland

09:45 – 10:20
The growing analytical toolbox for complex drugs : Assessment of NBCD bioequivalence
Scott McNeil / National Cancer Institute, USA

10:20- 10:40 BREAK

10.40 – 11:15
Global harmonization of regulatory processes. Are we still on time?
Falk Ehmann / European Medicines Agency, UK

11:15 – 11:50
Therapeutic equivalence of complex drug products: drifting, shifting of innovator and follow up versions. Case studies.
Paul Song / Samsung Bioepis, Korea

11:50 – 12:00
Concluding remarks
Stefan Mühlebach / University of Basel, Switzerland
& Daan Crommelin / Utrecht University, The Netherlands

With the support of: Non-Biological-Complex-Drugs (NBCD) Working Group and TUFTAD

WEDNESDAY MAY 24 09:00 - 12:00

E4 I ROOM A3

Big data, real world evidence and regulatory science

In recent years, progress in the collection, storage and analysis of real-world data has opened up promising avenues for pharmaceutical innovation. The challenge for the pharmaceutical sciences will be to harness this potential and utilize it to explore new treatment strategies and gather valuable evidence on the safety and effects of medicines in clinical practice. This session will discuss the current state and ways forward.

CO-CHAIRS
Songlin Xue / USA
Marieke De Bruine / Denmark

09:00 – 09:10
Opening remarks
Songlin Xue / Astellas, USA

09:10 – 09:45
Big data as source for pharmaceutical innovation
Arnold Chan / National Taiwan University, China Taiwan

09:45 – 10:20
Causal inferences from big data
Sara Eapen / Aetion Inc., USA

10:20 – 10:40 BREAK

10:40 – 11:15
Opportunities and challenges for Big Data to support regulatory decision making
Alison Cave / European Medicines Agency, UK

11:15 – 11:50
Are there any pre-clinical Big data?
Beatriz Lima / University of Lisbon, Portugal

11:50 – 12:00
Closing remarks
Marieke De Bruin / University of Copenhagen, Denmark

WEDNESDAY MAY 24 09:00 - 12:00

T4 | ROOM K16

Infectious diseases: the battle we have to win

CO-CHAIRS
Linda Hakes / UK
Ulf Janzon / Sweden

09:00 – 09:10
Opening remarks

09:10 – 09:45
Economic implications of antimicrobial resistance and ineffective treatments
Murray Aitken / Quintiles IMS Institute, USA

09:45 – 10:20
Scientific approaches to tackle antimicrobial resistance
Ron de Winter / COMBACTE, The Netherlands

10:20- 10:40 BREAK

10:40 – 11:15
Tackling tuberculosis
Klaus Romero / The Critical Path Institute, USA

11:15 – 11:50
Tropical parasitic diseases – the challenge of developing effective treatments
Alan Fairlamb / University of Dundee, UK

11:50 – 12:00
Closing remarks

WEDNESDAY MAY 24 13:30 - 15:00

13:30 - 15:00 I VICTORIA HALL
Plenary Closing Session

CHAIR
Bert Leufkens /
Utrecht University, The Netherlands

CO-CHAIR
Hiroshi Suzuki / University of Tokyo, Japan

13:30 – 13:35
Introduction by the chairs

13:40 – 14:50
Plenary closing debate
Panelists
Marilyn Morris / AAPS, USA
Erem Bilensoy / EUFEPS, Turkey
Per Artursson /
University of Uppsala, Sweden
Charlie Benrimoj /
University of Technology Sydney, Asutralia
Tomas Salmonsson /
Medical Products Agency, Sweden

14:50 – 15:00
Summary and concluding remarks
by the chairs





SHORT COMMUNI-CATIONS

A1

Drug Design, Fundamental & Translational Sciences

MON 22 MAY / **13:30-15:00**
ROOM K1
(10 min + 5 min Q&A for each presentation)

CHAIR
Takuya Kumamoto / Japan
CO-CHAIR
Rebecka Isaksson / Sweden

PSWC-ABS-1281
Towards the development of small molecule therapy for chikungunya
Christina Chai / Singapore
–
PSWC-ABS-1315
Fragment based simplification of Bedaquiline
Huaqing Cui / China, Germany, UK
–
PSWC-ABS-1333
A new adenosine analogue, COA-Cl can be a xeno free trophic factor
Ikuko Tsukamoto / Japan
–
PSWC-ABS-1730
Identification of aryl substituted pyrimidine derivatives dual targeting erα and vegfr-2 as anti-breast cancer agents
Hua Xiang / China
–
PSWC-ABS-1772
Engineering of KR-12 derived from human host defence peptide LL-37 into stable, selective and potent antimicrobial drug lead
Taj Muhammad / Sweden

A2

Drug Design, Fundamental & Translational Sciences

MON 22 MAY / **13:30-15:00**
ROOM K2
(10 min + 5 min Q&A for each presentation)

CHAIR
Michael Sorich / Australia
CO-CHAIRS
Nebojsa Mihajlica / Sweden

PSWC-ABS-1157
Optimization of drug delivery to tissues and avoiding drug induced phospholipidosis
Irena Loryan / Sweden, Germany, Netherlands
–
PSWC-ABS-1196
Evaluation of DILI predictive hypotheses in early drug development
Rosa Chan / USA
–
PSWC-ABS-1515
Magnetically bioprinted three dimensional scaffold-free liver model for nanotoxicity studies
Iqbal Ramzan / Australia
–
PSWC-ABS-1524
A comparison of two different self immolative linker strategies in the design of lymph directing, triglyceride mimetic prodrugs of buprenorphine
Sifei Han / Australia
–
PSWC-ABS-1573
Revealing multiple biochemical response patterns of remoxipride by integrating pharmacometabolomics and pharmacokinetic/pharmacodynamic modeling
Willem van den Brink / Netherlands, UK
–
PSWC-ABS-1731
Development of a novel method to estimate chronological changes of long-term progression of chronic diseases
Masashi Honma Japan

A3

Drug Design, Fundamental & Translational Sciences

TUES 23 MAY / **11:15-12:30**
ROOM K1
(10 min + 5 min Q&A for each presentation)

CHAIR
Stephan Schmidt / USA
CO-CHAIR
Stephanie Newman / Australia

PSWC-ABS-1276
Targeting TRPM2 signaling to relieve brain pericyte Injury
Lingxiao Shao / China
–
PSWC-ABS-1379
Blood-brain barrier transport of docosahexaenoic acid and expression of fatty acid binding protein 5 are decreased in Alzheimer's disease
Joseph Nicolazzo / Australia
–
PSWC-ABS-1404
The role of TLR4 in the gut-brain axis in Parkinson's disease: a translational study from man to mice
Aletta Kraneveld / Netherlands, USA
–
PSWC-ABS-1486
Unravelling the cause of the type 2 diabetes epidemic in South Asians: role for the endocannabinoid system?
Vasudev Kantae / Netherlands
–
PSWC-ABS-1719
The Y4-RNA fragment as a potential diagnostic marker
Tatsuya Ishikawa / Japan

B1

Drug Delivery & Targeting Sciences

MON 22 MAY / **13:30-15:00**
ROOM K11
(10 min + 5 min Q&A for each presentation)

CHAIR
Gerrit Borchard / Switzerland
CO-CHAIR
Ana Filipa Ferreira / Portugal

PSWC-ABS-1165
Quorum sensing inhibitors for pulmonary delivery as a novel treatment against Pseudomonas aeruginosa
Tomás Sou / Sweden, UK, Canada
–
PSWC-ABS-1170
Nanostructured liquid crystalline nanoparticles as carrier particles for delivery to bioactive surfaces
Nicole Bisset / Australia
–
PSWC-ABS-1488
A new method that enables in situ measurement of drug release from complex carrier-mediated systems
Caroline Alvebratt / Sweden
–
PSWC-ABS-1519
Drug supersaturation versus precipitation: experimental models of gastrointestinal absorption of fenofibrate from lipid-based delivery systems
Colin Pouton / Australia
–
PSWC-ABS-1566
DNP-NMR reveals the interior of lipid nanoparticle/mRNA formulations
Anna Schantz / Switzerland, USA, Sweden

B2

Drug Delivery & Targeting Sciences

MON 22 MAY / **13:30-15:00**
ROOM A2
(10 min + 5 min Q&A for each presentation)

CHAIR
Erem Bilensoy / Turkey
CO-CHAIR
Sybil Obuobi / Singapore

PSWC-ABS-1347
Uultrasound theranostics for tumor
Kazuo Maruyama / Japan
–
PSWC-ABS-1380
Intracellular environment-responsive lipid like material as a multi-nanoDDS platform
Hidetaka Akita / Japan
–
PSWC-ABS-1405
Effective cellular delivery of functional nucleic acids by faint electricity
Kentaro Kogure / Japan
–
PSWC-ABS-1441
Natural particulates inspired specific-targeted co-delivery strategy for collaborative antitumor therapy
Ruoning Wang / China
–
PSWC-ABS-1492
Sustainable sugar-based surfactants for innovative drug delivery systems
Luca Casettari / Italy, Hong Kong, UK

B3

Drug Delivery & Targeting Sciences

TUES 23 MAY / **11:15-12:30**
ROOM K2
(10 min + 5 min Q&A for each presentation)

CHAIR
Tetsuya Ozeki / Japan
CO-CHAIR
Hayley Schultz / Australia

PSWC-ABS-1100
New delivery systems for intranasal lipopeptide-based vaccine against group A streptococcus
Mariusz Skwarczynski / Australia
–
PSWC-ABS-1280
PEGylation relieves lipid nanoparticle-induced neuroinflammatory response in mouse brain and enhanced brain delivery for targeting ischemia
Yingmei Lu / China
–
PSWC-ABS-1427
Pharmacokinetics and preventive effects of platinum nanoparticles as reactive oxygen species scavengers on hepatic metastasis
Hidemasa Katsumi / Japan
–
PSWC-ABS-1527
A precision-guided MWNT mediated reawakening the sunk synergy in ras for anti-angiogenesis lung cancer therapy
Yujie Su / China
–
PSWC-ABS-1611
In vitro cytotoxicity and in vivo biodistribution of simvastatin-loaded lecithin/chitosan nanoparticles: nasal region as an appealing route for brain delivery
Adryana Clementino / Italy, Brazil, Australia

C1

Formulation & Manufacturing Sciences

MON 22 MAY / **13:30-15:00**
ROOM A3
(10 min + 5 min Q&A for each presentation)

CHAIR
Craig Johnston / USA
CO-CHAIR
Charlotte Bekker / Netherlands

PSWC-ABS-1123
Surface adhesion of pharmaceutical powders in relation to tableting performance
Maria Badal Tejedor / Sweden, Switzerland
–
PSWC-ABS-1225
Investigation of hydrophobic amino acids against moisture on in vitro aerosolization performance of highly hygroscopic spray-dried powders
Jiaqi Yu / Australia
–
PSWC-ABS-1308
Robustness aspects of continuous direct compressed HPMC based extended release tablets
Susanna Abrahmsén-Alami / Finland, Sweden
–
PSWC-ABS-1828
Orodispersible tablets based on spray-dried solid dispersions of furosemide
Ingunn Tho / Norway
–
PSWC-ABS-1876
Improving palatability and acceptability of oral multiparticulate formulations using hydrogels as administration vehicles
Felipe Lopez / UK

C2

Formulation & Manufacturing Sciences

TUES 23 MAY / **11:15-12:30**
ROOM K11
(10 min + 5 min Q&A for each presentation)

CHAIR
Shinji Yamashita / Japan
CO-CHAIR
Oliver Degerstedt / Sweden

PSWC-ABS-1200
3d scanning and SLA 3d printing for manufacturing topical drug delivery systems tailored to individual patients
Alvaro Goyanes / UK
–
PSWC-ABS-1317
A quality-by-design approach for highly systematic optimization of lipid-polymer hybrid nanoparticles toward efficient and safe intracellular delivery of siRNA cargo
Kaushik Thanki / Denmark
–
PSWC-ABS-1490
Design of printed tablets based on preformulation studies
Eva Jansen / Netherlands
–
PSWC-ABS-1686
Biologics loading on films through inkjet printing as potential buccal drug delivery systems
Javier Morales / Chile

D1

Regulatory Sciences

TUES 23 MAY / **11:15-12:30**
ROOM A2
(10 min + 5 min Q&A for each presentation)

CHAIR
Joseph Scheeren / Switzerland
CO-CHAIR
Mohammad Sofiqur Rahman / Japan

PSWC-ABS-1357
Poor medication adherence in clinical trials: consequences and solutions
Bernard Vrijens / UK, USA, Belgium
–
PSWC-ABS-1374
Evaluating quality of decision-making processes in medicines' development, regulatory review and health technology assessment: a systematic review of the literature
Magdalena Bujar / UK
–
PSWC-ABS-1411
Prescription analysis on community pharmacy servers for off-label use based on label text, age and dosage
Ole Jannik Bjerrum / Denmark
–
PSWC-ABS-1484
Risk perceptions of OTC drug use on a reregulated Swedish pharmacy market – with a special focus on paracetamol
Helle Håkonsen / Sweden
–
PSWC-ABS-1633
Mobile medical applications for dosage recommendation, drugs adverse reaction and drug interaction: review and comparison
Long Chiau Ming / Australia, Malaysia

E1

Science-based Practice

MON 22 MAY / **13:30-15:00**
ROOM K16
(10 min + 5 min Q&A for each presentation)

CHAIR
Martin Schulz / Germany
CO-CHAIR
Mare Oja / Estonia

PSWC-ABS-1071
Cardioselective beta blocker use in patients with chronic kidney disease: a national populati-on-based study
Ping-Hsun Wu / China, Taiwan
–
PSWC-ABS-1142
Assessment of the appropriate-ness of meningitis management and drug utilization: a prospec-tive audit for implementing an antimicrobial stewardship program
Ghada Elba / Egypt
–
PSWC-ABS-1265
The impact of inflammation and organ failure on CYP3A-mediated midazolam metabolism in critically ill children: predictive performance and extrapolation of a pediatric pharmacokinetic model
Janneke Brussee / Netherlands, France, USA, Switzerland
–
PSWC-ABS-1525
A systematic review of dementia and cognitive impairment risk with proton pump inhibitor therapy
Julia Fiona-Maree Gilmartin / Australia, UK
–
PSWC-ABS-1801
Sulfasalazine-induced agranulo-cytosis is associated with the human leukocyte antigen locus
Mia Wadelius / Sweden

E2

Science-based Practice

TUES 23 MAY / **11:15-12:30**
ROOM A3
(10 min + 5 min Q&A for each presentation)

CHAIR
Charlie Benrimoj / Australia
CO-CHAIR
Anna-Kaisa Rimpelä / Finland

PSWC-ABS-1266
A systematic and objective approach to the selection of nanomedicines and nanosimilars for clinical use
Beat Flühmann / Switzerland
–
PSWC-ABS-1371
Pharmacists' activities to mini-mise medication waste: an inter-national survey
Charlotte Bekker / Netherlands
–
PSWC-ABS-1507
Space for Pharmacy-based Interventions & Consultation Time Extension Study (SPICE): understanding potential challenges in implementing interventions in a community pharmacy-based setting
Elise El-Boustani / Australia
–
PSWC-ABS-1638
Medication errors in the older adult population: a systematic review
Long Chiau Ming / Australia, Malaysia

T1

Education & Training

TUES 23 MAY / **11:15-12:30**
ROOM K16
(10 min + 5 min Q&A for each presentation)

CHAIR
Masaru Kato / Japan
CO-CHAIR
Eko Setiawan / Indonesia

PSWC-ABS-1667
Active learning techniques in a pharmaceutical analytical chemistry laboratory course to improve student performance
Joanna Toralba / Philippines
–
PSWC-ABS-1839
Creating 'community' as a tool for innovation in pharmaceutical science education; the meeting of academics, industrial scientists, graduate students, undergraduate students and the general public
Cristina de Matteis / UK
–
PSWC-ABS-1842
An analysis of current global pharmacy workforce 2013-2015
Rammah Mustafa / Sweden, UK
–
PSWC-ABS-1960
Knowledge, awareness, and attitudes toward antibiotic use and antimicrobial resistance
Mohamed El Zowalaty / South Africa, Czech Republic



SHORT
COURSE

SHORT **COURSE**

ROOM K13

Drug transporters in ADME

The course will deal with the role of membrane transport proteins in determining the ADME properties of drug candidates and substances. We will give an overview of drug transporters in barrier tissues, with emphasis on transporters that mediate intestinal absorption/efflux and drug disposition to the brain (transporters in the blood brain barrier). Lectures will cover basic concepts such as flux, permeability, barrier tissue biology, transporter kinetics and transporter structure and function. This will be supplemented with a description of the in vitro methods for studying drug transport/transporters in tissue models. Finally, we will present the EMEA/FDA-guidelines for investigating transporter interactions and discuss how this may be integrated in a drug development context.

COORDINATOR
Birger Brodin / University of Copenhagen

ORGANISED BY
Carsten Uhd Nielsen
Bente Steffansen &
Birger Brodin

CO-CHAIRS
Carsten Uhd Nielsen /
University of Southern Denmark
Bente Steffansen /
University of Southern Denmark
Birger Brodin /
University of Copenhagen

SUNDAY MAY 21

07:00 – 08:00
Breakfast

08:00
Opening

08:00 – 09:00
Overview of transporters and organs relevant to determining ADME properties of drug compounds
Carsten Uhd Nielsen

09:00 – 10:00
Basic transporter kinetics and barrier tissues
Birger Brodin

10:00 – 10:30 COFFEE

10:30 – 11:30
Advanced transporter kinetics, multiple transporters
Bente Steffansen

11:30 – 12:30
Intestinal transport, models to study transport and transporters
Carsten Uhd Nielsen

12:30 – 13:00 LUNCH

13:00 – 14:00
The role of transporters at the blood brain barrier; uptake and efflux mechanisms
Birger Brodin

14:00 – 15:00
Regulatory aspects of drug transporters
Bente Steffansen

15:00
Closure

MEET THE **SIG MEETINGS**

SIG MEETING

Regulatory Sciences

MONDAY 22 MAY
12:00 – 12:30

Jennifer Dressman
ROOM K11

SIG MEETING

Formulation Design & Pharmaceutical Technology

MONDAY 22 MAY
12:00 – 12:30

Jayne Lawrence
ROOM K2

SIG MEETING

Analytical Sciences & Pharmaceutical Quality

MONDAY 22 MAY
13:00 – 13:30

Daniel Tang / Masaru Kato
ROOM K16

SIG MEETING

Pharmacy Practice Research

TUESDAY 23 MAY
07:30 – 08:00

Charlie Benrimoj / Martin Schulz
ROOM A3

SIG MEETING

Translational Research & Individualized Medicines

TUESDAY 23 MAY
13:00 – 13:30

Michael Sorich
ROOM K16

SIG MEETING

Drug Design & Discovery

WEDNESDAY 24 MAY
12:00 – 12:30

Takuya Kumamoto
ROOM K11

SIG MEETING

Biotechnolgy

TUESDAY 23 MAY
07:30 – 08:00

Binodh De Silva
ROOM K16

7th FIP Pharmaceutical Sciences World Congress (PSWC)

Montreal, Canada
22-27 May 2020

The Global Rise of Precision Medicine

Context Appropriate Interventions from Target to Market

PSWC 2020:
*A **MUST** FOR **ALL** INVOLVED IN THE PHARMACEUTICAL SCIENCES*



We live in exciting times. Our ability to collect, store and analyze data is growing exponentially, creating new opportunities to understand and influence biological processes. A major outcome of systems approaches in life sciences and therapeutics is the rise of precision medicine on a global scale. The impact will be felt at both the individual and population levels.

The Pharmaceutical Sciences World Congress 2020 invites scientists from all over the world to an exciting meeting to discuss and explore how Precision Medicine can have a global yet context appropriate impact on therapeutic interventions, from target to market. We will examine current challenges and future prospects for drug discovery, development and clinical usage for the individual patients, for the communities, small and large, as well as for the pharmaceutical scientists themselves across the world.

Welcome to Montreal!

Welcome to Montreal!

Just walking the streets of Montreal is an experience, especially the historic centre known as Old Montreal, which provides a window into the city's rich history with its cobblestone streets and architectural styles ranging from the 16th century to the present.

Montreal's museums, landmarks, shopping districts, restaurants and clubs will provide more entertainment than you will have time for!

JOIN US IN MONTREAL *AND BE INSPIRED!*



fip

MONTREAL PSWC 2020
22-27 May

CSPS

Université de Montréal

EVENTS

Opening Ceremony

SUNDAY 21 MAY / 16:00 – 18:00
VICTORIA HALL

Full programme: please see page 30.

Welcome Reception

SUNDAY 21 MAY / 18:00 – 19:00
EXHIBITION HALL

The organizers of PSWC invite all participants and accompanying persons for a warm and festive welcome reception at the exhibition hall immediately after the opening ceremony.

Reception at the City Hall of Stockholm

MONDAY 22 MAY / 19:00 – 20:00
CITY HALL OF STOCKHOLM
Hantverkargatan 1, Stockholm



The Stockholm City Hall is one of Sweden's most famous buildings, and one of the capital's most visited tourist attractions. It is famous for its grand ceremonial halls and unique art pieces and is the venue of the Nobel Prize banquet held on 10th of December each year.

Congress Dinner

TUESDAY 23 MAY / 19:30 – 22.30
SKANSEN
Djurgårdslätten 49-51 / Stockholm



The Congress dinner will take place on Tuesday 23 May as of 19.30 hours at Skansen:
Skansen Djurgårdsslätten 49-51, Stockholm

Skansen is the world's first open-air museum, founded in 1891. Here you can stroll through five centuries of Swedish history, from north to south, with a real sense of the past all around in the historical buildings and dwellings, peopled by characters in period dress. Tickets can be purchased via the online Congress Registration Form.

Breaks

During the session breaks complimentary coffee and tea will be available for all participants in the exhibition hall.
Lunch is not included at this congress but there are food stations and restaurants in the congress center to cater for your needs.

WIFI

The SSID (network) Stockholmsmässan is an open network without password.

EXHIBITION

A three day exhibition will complement the 6th Pharmaceutical Sciences World Congress in the Stockholmsmässan in Stockholm.

From May 21-24, 2017, exhibitors and sponsors are invited to take advantage of extensive, high quality showcase opportunities, bringing the best of their products, services and organisations to the public eye.

The PSWC 2017 exhibition offers the perfect opportunity to raise your organisation's profile and build relationships with key decision makers within the pharmaceutical sciences industry.
If your organisation has an interest in this sector, you cannot afford to miss this opportunity.
The industry exhibition will be the hub of the event, hosting all congress refreshment breaks as well as posters, guaranteeing an excellent through-put of congress delegates.

Opening hours Exhibition Hall

SUNDAY 21 MAY /
18:00 – 19:00 (Welcome Reception)
–
MONDAY 22 MAY /
09:00 – 18:00
–
TUESDAY 23 MAY /
09:00 – 18:00
–
WEDNESDAY 24 MAY /
09:00 – 14:00





REGISTRATION ON SITE

All costs referred to are in Euro €. 25% Swedish VAT is charged on each registration as mentioned. The Swedish VAT registration number is: SE502076121801	**Onsite**	
	excl. VAT	*incl. VAT*
Participants	850,00	1.062,50
Students/ Recent Graduates	850,00	1.062,50
Accompanying person	150,00	187,50
Day cards	350,00	437,50
Congress dinner Tuesday 23 May	80,00	100,00
Young Scientist Satellite Conference Friday 19 May – Sunday 21 May – *can only be purchased in combination with main congress*	150,00	187,50

Opening hours registration desk

Saturday 20 May	07:30 – 17:30
Sunday 21 May	07:30 – 17:30
Monday 22 May	07:30 – 17:30
Tuesday 23 May	07:30 – 17:30
Wednesday 24 May	07:30 – 15:30

Registration fee for participants and students / recent graduates includes:

- Admission to all sessions
- Opening Ceremony & Welcome Reception in the Exhibition hall
- Entrance to the Exhibition
- Access to all submitted Abstracts and Biographies as of 1 May 2017
- Congress Bag with Final Congress Programme (including list of participants *(name and country of participants registered and paid by 15 April 2017)*
- Access to a website where you can download the (slides of the) presentations *(available as of 1 July 2017)*
- Coffee/tea breaks

Please note that lunch is NOT included at this congress.

Registration fee for accompanying persons includes:

- Opening Ceremony
- Welcome Reception
- Entrance to the Exhibition

Please note that lunch is NOT included at this congress. The fee for accompanying persons does NOT include admission to the sessions.

CONTACT

Congress information

FIP Congresses & Conferences
Andries Bickerweg 5
2517 JP The Hague
The Netherlands
Office opening hours:
Monday to Friday 09:00 – 17:00 CET
–
T +31 70 302 19 82
F +31 70 302 19 98
pswc@fip.org
http://pswc2017.fip.org/

Registration, abstract handling & housing

MCI Amsterdam
Schipluidenlaan 4
1062 HE Amsterdam
The Netherlands
Office opening hours:
Monday to Friday 09:00 – 17:00 CET
–
T +31 20 575 42 20
F +31 20 673 73 06
pswc@mci-group.com

Official Carrier

SKYTEAM
GLOBAL MEETINGS
Official Alliance Network



POSTER SESSIONS

MONDAY MAY 22 & TUESDAY MAY 23

12:00 – 14:00 | EXHIBITION HALL

A — Drug Design, Fundamental & Translational Sciences

SESSION	TOPIC	DATE / TIME	# POSTERS	NUMBERS
A1	**Drug Design**	**MON**DAY 22 12:00 – 13:30	58	P-A-001 – P-A-058
A2	**Fundamental Sciences**	**MON**DAY 22 12:00 – 13:30	54	P-A-060 – P-A-114
A3	**Translational Sciences**	**TUES**DAY 23 12:30 – 14:00	94	P-A-001 – P-A-094

B — Drug Delivery & Targeting Sciences

SESSION	TOPIC	DATE / TIME	# POSTERS	NUMBERS
B1	**Fundamental Pharmaceutics**	**MON**DAY 22 12:00 – 13:30	58	P-B-001 – P-B-058
B2	**Drug Delivery**	**TUES**DAY 23 12:30 – 14:00	69	P-B-001 – P-B-069
B3	**Non-clinical Development**	**TUES**DAY 23 12:30 – 14:00	47	P-B-070 – P-B-117

C — Formulation & manufacturing sciences and quality control

SESSION	TOPIC	DATE / TIME	# POSTERS	NUMBERS
C1	**Conventional Dosage Forms**	**MON**DAY 22 12:00 – 13:30	76	P-C-001 – P-C-076
C2	**Novel Dosage Forms**	**TUES**DAY 23 12:30 – 14:00	45	P-C-001 – P-C-045

OVERVIEW

The poster area in the Exhibition Hall is open to all registered participants and their registered accompanying persons.

D

Regulatory Science

SESSION	TOPIC	DATE / TIME	# POSTERS	NUMBERS
D	**Regulatory Science**	**MON**DAY 22 12:00 – 13:30	23	P-D-001 – P-D-023

E

Science-based Practice

SESSION	TOPIC	DATE / TIME	# POSTERS	NUMBERS
E1	**General**	**MON**DAY 22 12:00 – 13:30	43	P-E-001 – P-E-043
E2	**Drug/Disease Focused**	**TUES**DAY 23 12:30 – 14:00	43	P-E-001 – P-E-043

T

Education & Training

SESSION	TOPIC	DATE / TIME	# POSTERS	NUMBERS
T	**Education & Training**	**TUES**DAY 23 12:30 – 14:00	15	P-T-001 – P-T-015

Instructions for presenters

If your poster is scheduled for
MONDAY 22 MAY
- Hang up poster between 08:00 and 12:00
- Be at poster board between 12:00 and 13:30
- Take down poster between 14:00 and 16:00

If your poster is scheduled for
TUESDAY 23 MAY
- Hang up poster between 08:00 and 12:00
- Be at poster board between 12:30 and 14:00
- Take down poster between 14:00 and 16:00

Waiver of liability

*All poster presenters are responsible for putting up and removing their own poster in a proper way and **strictly within the indicated timeslots.***

If presenters hang their poster too early or do not remove their poster in time, FIP is not responsible for any damage that might happen to the poster when it has to be removed by staff members.

LIST OF PARTICIPANTS

Afghanistan
Abdul Wali Aziz
Danial Wali Aziz
Rangina Aziz
Wazhma Aziz
Mohammad Osman Zaki

Number of participants from Afghanistan: 5

Argentina
María Virginia Giolito
María José Rico
Micaela Ventura

Number of participants from Argentina: 3

Australia
Kevin Batty
Charlie Benrimoj
Ben Boyd
Susan Charman
William Charman
Timothy Chen
Carwyn Davies
Tahnee Dening
Elise El-Boustani
Julia Gilmartin-Thomas
Sifei Han
Ran Liu
Kellie May
Ross McKinnon
Long Ming
Sayan Mitra
Stephanie Newman
Joe Nicolazzo
Anna Pham
Christopher Porter
Colin Pouton
Clive Prestidge
Eileen Quin
Iqbal Ramzan
Shasha Rao
Stephanie Reuter Lange
Lloyd Sansom
Hayley Schultz
Mariusz Skwarczynski
Michael Sorich
Julie Varghese
Lynn Weekes
Desmond Williams
Jiaqi Yu

Number of participants from Australia: 34

Austria
Bettina Digruber
Nélio Drumond
Walter Jaeger

Number of participants from Austria: 3

Belgium
Philippe Berben
Magda Chlebus
Mariana Constantinovici
Jo Demeester
Pierre Meulien
Raluca Radu
Pascale Redig
Danny Riethorst
Jari Rubbens
Jef Stappaerts
Thomas Steckler
Jens Van Den Abeele
Karen Vermuyten
Bernard Vrijens

Number of participants from Belgium: 14

Bosnia and Herzegovina
Vedada Čeljo
Selma Zukic

Number of participants from Bosnia and Herzegovina: 2

Brazil
Terezinha De Jesus Andreoli Pinto
Daniel Bezerra
Thais Ferreira
Ederson Laurindo
Holanda De Sousa
Lorena Malaquias
Abayomi Ogunjimi
Paula Oliveira
Ismael Rosa

Number of participants from Brazil: 8

Bulgaria
Svetla Georgieva
Kalinka Staneva
Zahari Vinarov

Number of participants from Bulgaria: 3

Cameroon
Ajeck Awum Becky
Clement Ndon Che
Dutrong Romuald Tsague

Number of participants from Cameroon: 3

Canada
Denis Deblois
Andrea Edginton
Celine Fiset
Jeanne Leblond Chain
Kamal K. Midha
Neelam Midha
Robert Sindelar
Ross Tsuyuki

Number of participants from Canada: 8

Chile
Javier Morales

Number of participants from Chile: 1

China
Weimin Cai
Kerong Chen
Qiufang Chen
Huaqing Cui
Ru Feng
Yikun Gao
Yuan Gao
Zhonggao Gao
Tingting Guo
Feng Han
Xue Han
Xiao Min Hu
Ping Huang
Guojun Jiang
Yan Li
Dongchun Liu
Wei Liu
Yin Liu
Yingmei Lu
Yicheng Mao
Lingxiao Shao
Yujie Su
Daniel Tang
Yuan Feng Tong
Dan Wang
Jiang Wang
Lei Wang
Ling Wang
Ruoning Wang
Siling Wang
Wei Wang
Xiaojian Wang
Xiaoliang Wang
Tang Weiwei
Hui Wen
Meiyang Xi
Guimin Xia
Hua Xiang
Qiong Xiao
Dongming Zhang
Jing Zhang
Xiang Zhang (2x)
Ailian Zheng
Zu-Guo Zheng
Zhiyuan Zhong
Jie Zhu
Ningyu Zhu
Sheng Zhu

Number of participants from China: 49

China, Hong Kong SAR
Joan Zuo

Number of participants from China, Hong Kong SAR: 1

China Taiwan
Arnold Chan
Yong Chieh Chang
Tun-Chieh Chen
Yan-Ping Chen
Fu-Jen Cheng
Wei Ho
Ching-Yi Hsu
Jaw-Jou Kang
Wen Hsun Lee
Jih-Heng Li
Chun Han Lin
Chun-Jung Lin
Yi-Ting Lin
Chaolin Liu
Chia-Rui Shen
Ming-Ta Tsai
Ping-Hsun Wu

Number of participants from China Taiwan: 17

Croatia
Anita Hafner
Milena Jadrijevic Mladar Takac
Bisera Jurišić Dukovski
Jasmina Lovrić ć
Zrinka Rajic Dzolic
Miranda Sertic

Number of participants from Croatia: 6

Denmark
Irina Elena Antonescu
Ole Jannik Bjerrum
Birger Brodin
Vibeke Dalhoff
Marieke De Bruin
Camilla Foged
Sven Frokjaer
Christoffer Gerner
Bavnhøj Hansen
Jens Heisterberg
Jens Kateb
Martin Kruusmägi
Flemming Madsen
Janni Mortensen
Anette Müllertz
Jukka Rantanen
Anette Seo Torstenson
Rikke Løvig Simonsen
Bente Steffansen
Kaushik Thanki
Prasad Walke
Jorrit Water

Number of participants from Denmark: 21

Egypt
Amal Kamal Abdel-Aziz
Ghada Elba

Number of participants from Egypt: 2

Estonia
Jyrki Heinämäki
Ivo Laidmäe
Mare Oja

Number of participants from Estonia: 3

Ethiopia
Eyob Alemayehu Gebreyohannes

Yonas Getaye Tefera
Henok Tegegn

Number of participants from Ethiopia: 3

Finland
Ida Alanko
Daria Demidenok
Sari Häkkinen
Emma Heikkinen
Päivi Hirvensalo
Jouni Hirvonen
Kristiina M. Huttunen
Sanja Karlsson
Anssi-Pekka Karttunen
Jarkko Ketolainen
Mikko Koskinen
Kaisa Kyttä
Mikko Niemi
Heidi Öblom
Ezgi Özliseli
Narayana Prakirth Özliseli
Giorgia Patrignani
Laura Pelkonen
Maren Katherina Preis
Jhinuk Rahman
Eva Ramsay
Anna-Kaisa Rimpelä
Jessica Rosenholm
Outi Salo-Ahen
Niklas Sandler
Erica Sjöholm
Eeva Teräsalmi
Johanna Tuunainen
Hossein Vakili
Henrika Wickström
Emrah Yildir

Number of participants from Finland: 31

France
Nicolas Azzopardi
Fabienne Franck
Jeremie Guedj
Ana Gutierrez
Vincent Jannin
William Raoul
Aurélie Rochefolle
Jean-Michel Scherrmann

Number of participants from France: 8

Germany
Veronika Braig
Jennifer Dressman
Anna-Carola Eicher
Eva Beate Goebgen
Bastian Haering
Linda Hakes
Simone Hansmann
Roland Heinig
Bärbel Holbein
Jens Holtappels
Edmund Hoppe
David Jackson
Charlotte Kloft
Andreas Koczwara
Twan Lammers
Annette Mende
Anita Nair
Christina Rödel
Anna Rutkowska-Klute
Christopher Sack
Bernhard Schmid
Martin Schulz
Dieter Steinhilber
Dimitrios Tzalis
Francis Williams Ojara
Sandra Wittmann

Number of participants from Germany: 26

Ghana
Patience Abeka
Joe Adu-Manuh
Emmanuel Agyapong
Leticia Mensah Boakye
Henry Darko
Frempong Manso Kwabena

Number of participants from Ghana: 6

Greece
Ioannis Daravigkas
Costas Demetzos
Konstantinos Kipouros
Nikoleta Kouri
Panos Macheras
Natassa Pippa
Maria Vertzoni

Number of participants from Greece: 7

Hungary
Anita Chvatal
Ildiko Csoka
Orsolya Gyulai
Barbara Sipos
Eva Szoko
Tímea Tari

Number of participants from Hungary: 6

Iceland
Kristinn Gudnason

Number of participants from Iceland: 1

India
Deepak Prabhakar Bhagwat
Padmini Iriventi
Sangeetha Iyer
Jaya Gopal Meher
Hasimuddin Mohammed
Sameeruddin Mohammed
Younes Mohebi
Chandni Saha
Vandana Sethi
Kanika Thakur
Nayanabhirama Udupa
D. Krishna Veni
Narayanan Venkateshan
Lavakumar Vuppalapati
Geeta Yadav
Sepideh Zarenejad

Number of participants from India: 16

Indonesia
Yahdiana Harahap
Diky Mudhakir
Retno Murwanti
Heni Rachmawati
Eko Setiawan
Sri Wahyuningsih

Number of participants from Indonesia: 6

Iran
Shayesteh Amin
Shokouh Arjmand
Mina Behzadi
Sara Ezzatabadipour
Mehri Javid
Samira Khajeh
Mahmoodreza Moein
Hanie Mohammadzadeh
Pooria Sabouri
Saeed Taheri

Number of participants from Iran: 10

Iran
Dunya Al-Duhaidahawi
Jamal Almulla
Ali Altaee

Number of participants from Iraq: 3

Ireland
David Brayden
Ken Howick

Number of participants from Ireland: 2

Israel
Dan Peer

Number of participants from Israel: 1

Italy
Luca Casettari
Adryana Clementino
Diego Romano Perinelli
Irene Rossi
Fabio Sonvico

Number of participants from Italy: 5

Japan
Akira Adachi
Keiko Akagawa
Hidetaka Akita
Tomomi Akita
Ahmed Ali
Takehisa Hanawa
Tamami Haraguchi
Mitsuru Hashida
Mai Hashimoto
Mayuko Hatai
Mai Hazekawa
Yuriko Higuchi
Masahiko Hirafuji
Masahiro Hiratsuka
Akihiko Hirose
Mamiko Hishikawa
Masto Homma
Masashi Honma
Hisako Ibaraki
Hiroshi Iijima
Daisuke Inoue
Ken-Ichi Inui
Daisuke Iohara
Tatsuro Irimura
Ryohei Ishiba
Tatsuya Ishikawa
Takaaki Ito
Masahiro Iwaki
Noriyasu Kamei
Takanori Kanazawa
Takahiro Kasai
Masaru Kato
Yukio Kato
Hidemasa Katsumi
Junichi Kawakami
Masashi Kawami
Tatsuya Kawasaki
Atsushi Kawase
Kataoka Kazunori
Akihito Kiguchiya
Hidenori Kimura
Kotaro Kimura
Eriko Kinoshita
Hiroaki Kitano
Akihiko Komuro
Ryoji Konishi
Michaki Kubo
Takuya Kumamoto
Masatomo Maeda
Kazuo Maruyama
Jun Miura
Naoya Miura
Yukari Miyadera
Yurina Miyashita
Hiroshi Miyata
Keiichi Motoyama
Tomohiro Nabekura
Tsuneji Nagai
Ayumu Nagamine
Yoshinori Nagata
Nishiki Nagaya
Takafumi Naito
Kazuki Nakamura
Tomohiro Nishimura
Wataru Obuchi
Kayoko Ohura
Yuko Okamoto
Masahiro Okuda
Tomoyuki Okuda
Akira Otaka
Tetsuya Ozeki
Mohammad Sofiqur Rahman
Yoshimichi Sai
Hitoshi Sasaki
Tadanori Sasaki
Masanobu Sato
Saki Shiga
Hiroaki Shimada

LIST OF PARTICIPANTS

Saori Shimada
Yohsuke Shimada
Takumichi Sugihara
Yuichi Sugiyama
Hiroshi Suzuki
Kazuaki Taguchi
Tappei Takada
Hiroyuki Taki
Akiko Tanaka
Hiroki Tanaka
Sachiko Tanaka
Hiroshi Terada
Reiko Teraoka
Masahiro Tokuno
Toshiyoshi Tominaga
Kota Toshimoto
Masayoshi Tsubuki
Ikuko Tsukamoto
Akihiro Watari
Kaori Yama
Kojiro Yamamoto
Nobuo Yamamoto
Takehito Yamamoto
Shinji Yamashita
Shugo Yamashita
Noriko Yoshikawa
Mikiko Yutani
Reiko Yutani

Number of participants from Japan: 106

Jordan
Zaid Alazzawi
Suhair Al-Nimry
Mostafa Alslity
Rania Hamed
Mohammad
Mohammad
Sarah Mohammed
Naji Najib
Rabab Tayyem
Ahlam Zaid Alkilani

Number of participants from Jordan: 9

Kenya
Edwin Maua

Number of participants from Kenya: 1

Korea, Republic of
Hoo Kyun Choi
In Koo Chun
Hyo-Kyung Han
Kyungsun Heo
Soon Sun Hong
Sung-Joo Hwang
Hyun-Il Jo
Hong Kee Kim
Hyun Sook Kim
Sung Jin Kim
You-Sun Kim
Sung Won Kwon
Beom-Jin Lee
Mi-Kyung Lee
Kyung Taek Oh
Eun-Seok Park
Jeong-Sook Park
Jun-Bom Park
Dongchul Shin
Dong Hwan Sohn
Hosup Song
Paul Song

Number of participants from Korea, Republic of: 22

Lebanon
Lydia Rabbaa Khabbaz

Number of participants from Lebanon: 1

Liberia
Keturah Smith

Number of participants from Liberia: 1

Macedonia
Metodi Keskovski
Nevena Solevska

Number of participants from Macedonia: 2

Malaysia
Inas Aldhaee
Alice Chuah
David Gonsalvez

Number of participants from Malaysia: 3

Montenegro
Katarina Milosevic
Kostadinovic
Milanka Zugic

Number of participants from Montenegro: 2

Nepal
Pradip Lamsal
Kalpana Parajuli-Baral
Pushpa Sharma

Number of participants from Nepal: 3

The Netherlands
Charlotte Bekker
Ad Bernaerts
Luc Besançon
Emma Boyd
Douwe Breimer
Branka Brglez
Janneke Brussee
Ka-Chun Cheung
Paula Cohen
Sinziana Cristea
Daan Crommelin
Meindert Danhof
Elizabeth De Lange
Jon De Vlieger
Ron De Winter
Wilbert De Witte
Helga Gardarsdottir
Sebastiaan Goulooze
Erwin Hietland
Hubertus Irth
Jorg Janssen
Vasudev Kantae
Kevin Klein
Catherijne Knibbe
Bert Leufkens
Adlan Magomedov
Barend Mons
Catharine Rademaker
Ton Rijnders
Laurien Rook
Jan Schellens
Pieter Stolk
Mireille Swakhoven
Jesse Swen
Miranda Van Beers
Willem Van Den Brink
Carola Van Der Hoeff
Oliver Van Der Spek
Rachel Van Kesteren
Ron Van Schaik
Rob Van Wijk
Lin-Nam Wang
Yin-Cheong Wong
Yumi Yamamoto

Number of participants from Netherlands: 45

Nigeria
Adewale Adenugba
Adisa Adesina Raheem
Chimezie Anyakora
Olusola Aremu
Fatima Abosede Costa
Anthonia Dunkwu
Ikponmwosa Cliff Ediae
Ejiofor Ikechukwu Michael
Adeola Kola-Mustapha
Jacob Kolawole
Ugochinyere Ogudu
Bode Olatunji
Ozioma Onokala
Temitope Oyeneye
Obasanya Sunday Gbenga
Ngozi Udem

Number of participants from Nigeria: 16

Norway
Malgorzata Adamczak
Øyvind Bosnes Engen
Per Kristian Faksvåg
Margherita Falavigna
Goril Eide Flaten
Henrik Schultz
Natasa Skalko-Basnet
Ingunn Tho

Number of participants from Norway: 8

Oman
Asma Araba

Number of participants from Oman: 1

Pakistan
Faqeer Muhammad Shaikh

Number of participants from Pakistan: 1

Philippines
Bryan Paul Bulatao
Joanna Toralba `

Number of participants from Philippines: 2

Poland
Anna Krupa
Jakub Okoniewski
Magdalena Ozimek

Number of participants from Poland: 3

Portugal
Hugo Almeida
Pedro Barrocas
Ana Francisca Bettencourt
Fernando Fernandez-Llimos
Ana Filipa Ferreira
Rogerio Gaspar
Beatriz Lima
Luis Monteiro Rodrigues
Jose Morais
Ema Paulino
Alda Pereira Da Sillva Oliveira
Isabel Ribeiro
Ana Silva
Ana Margarida Silva
Henrique Silva

Number of participants from Portugal: 15

Romania
Maria Bianca Abrudan
Elena Fasniuc
George Mihai Nitulescu
Georgiana Nitulescu
Bianca Sylvester
Lucia Tefas
Andrei Valeanu

Number of participants from Romania: 7

Russian Federation
Natalia Chukreeva
Oleg Demin
Mikhail Khvostov

Number of participants from Russian Federation: 3

Saudi Arabia
Jabal Alotaibi
Haitham Hekal

Number of participants from Saudi Arabia: 2

Serbia
Nina Dragicevic
Renata Gocic-Petrovic
Branka Grujic
Aleksandra Lukacevik
Danijela Pecarski
Branka Rados-Grabez

Number of participants from Serbia: 6

Singapore
Christina Chai
Han Kiat Ho
Sybil Obuobi
Giorgia Pastorin
Bernice Mei Jin Tan
Paul Wan Sia Heng

Number of participants from Singapore: 6

South Africa
Dube Admire

Number of participants from South Africa: 1

Spain
Maria José Alonso
Esther Caparros
José Antonio Cordero
Ana Andrea Garcia Sacristan
Tamara Gómez Dacoba
Jorge Manzanares
Francisco Javier Manzano Lista
Conxita Mestres
Francisco J Otero-Espinar
Carmen Peña López
Ferran Sanz

Number of participants from Spain: 12

Sri Lanka
Umanda Nethmini Ekanayake
Kowmica Skantharajah

Number of participants from Sri Lanka: 2

Sweden
Bertil Abrahamsson
Susanna Abrahmsén Alami
Rasel A Al-Amin
Göran Alderborn
Amjad Alhalaweh
Amani Al-Hayali
Linda Alskär
Caroline Alvebratt
Sara Amberntsson
Sara Andersson
Ulrika Andersson
Patrik Aronsson
Per Artursson
Maria Badal Tejedor
Lisa Bandholtz
Nils Bergeå
Mats Berglund
Annika Bergman
Christel Bergström
Erik Björk
Anders Blanck
Mikael Boberg
Lukas Boge
Kathryn Browning
Johan Bylund
Helena Bysell
Sara Carlert
Anna Collén
Flavia Cuibus
Louis De Scheerder
Oliver Degerstedt
Ilse Dubbelboer
Martin Eklund
Johanna Eriksson
Ulf Eriksson
Jonas Fagerberg
Anders Falk
Gustav Ferrand-Drake Del Castillo
Anne M Filppula
Staffan Folestad
Sara Frykstrand
Rydvikha Govender
Anders Grahnén
Torkel Gren
Christina Gustafsson
Sofia Gustafsson
Margareta Hammarlund-Udenaes
Niklas Handin
Annelie Hansson
Anna Hardmeier
Oliver Hedge
Ingrid Helander
Katarina Hellander
Adriaan Hendrickx
Yang Hu
Moustafa Ibrahim
Karin Inadsson
Rebecka Isaksson
Ulf Janzon
Jonas Johansson
Märit Johansson
Marcus Josefsson
Azadeh Karami
Anders Karlén
Maria Karlgren
Eva Karlsson
Janneke Keemink
Lucia Kovac
Annika Kyssä
Per Larsson
Jacob Leander
Hans Lennernäs
Hans Linden
Tuulikki Lindmark
Sofia Linnros
Patrik Lundquist
Alexander Mammoo
Åsa Månsson
Wiking Månsson
André Mateus
Pär Matsson
Sofia Matsson
Johanna Melin
Karin Meyer
Gabrielle Meyerson
Nebojsa Mihajlica
Taj Muhammad
Jan Neelissen
Pär Nordell
Magnus Ölander
Jenny Ottosson
Albin Parrow
Rezvan Parvizi
Ann-Sofie Persson
Ingrid Persson
Karin Persson
Fatemeh Sepideh Pirdehghan
Susanne Prothon
Jonas Rudén
Muhammad Waqas Sadiq
Tomas Salmonson
Nasim Samiei
Anna Schantz
Erik Sjögren
Karin Skansen
Sara Solin
Tomás Sou
Michael Sundström
Pirjo Tajarobi
Ulrika Tehler
Ursula Thormann
Andrea Treyer
Mathias Uhlen
Charlotta Vedin
Parameswara Rao Vuddanda
Mia Wadelius
Ulrika Wählby Hamren
Shijun Wang
Christine Wegler
Gustaf Wellhagen
Marc Willuhn
Emma Winberg
Chenyan Zhao
Wenyi Zheng

Number of participants from Sweden: 125

Switzerland
Jörg Berghausen
Susanne Birmoser
Gerrit Borchard
Andrea Botomino
Michel Buchmann
Olivier Bugnon
Monica De Bardi
Dominique Ditter
Claudia D'uscio
Beat Flühmann
Christina Häuser
Dominique Jordan
Somnath Kandekar
Atanas Koulov
Eleanor Lindenberg
Hanns-Christian Mahler
Annie Mayence
Stefan Mühlebach
Alain Munafo
Hanu Ramachandruni
Facundo Santomé
Joseph Scheeren
Jean Jacques Vanden Eynde
Tania Weng

Number of participants from Switzerland: 24

Tanzania
Bamileki Ally Khalfani

Number of participants from Tanzania: 1

Thailand
Sirawan Gunsuang
Napaphak Jaipakdee
Thitinun Karpkird
Ekapol Limpongsa
Auraya Manaprasertsak
Worranan Rangsimawong
Karunrat Tewthanom
Prasopchai Tonglairoum
Pamika Tunpanich
Amolnat Tunsirikongkon
Weerapath Winotapun
Thisirak Woraphatphadung

Number of participants from Thailand: 12

Turkey
Erem Bilensoy
Emre Şefik Çağlar
Nevin Çelebi
Erdogan Colak
Burak Demir
Gulengul Duman
Sedef Erdal
Sevgi Güngör
Atilla A. Hincal
Alptug Karakucuk
Ahmet Özdemir
Yildiz Ozsoy Erginer
Selma Sahin
Genada Sinani
Nilufer Tarimci
Serdar Tort
Arman Uney
Neslihan Üstündağć Okur
Vildan Yozgatli

Number of participants from Turkey: 20

Ukraine
Anastasiia Bakun

Number of participants from Ukraine: 1

United Arab Emirates
Bhoomendra Bhongade
Najeba Chams Eddin

LIST OF PARTICIPANTS

Essam Tawfik

Number of participants from United Arab Emirates: 3

United Kingdom

Muhammad Fauzi Bin Abd Jalil
Lamya Abdi
Sean Askin
Charlotte Bain
Susan Barker
Alasdair Breckenridge
Jurgen Brem
Magdalena Bujar
Richard Clark
Aidan Cooper
Duncan Craig
Cristina De Matteis
M Begona Delgado-Charro
Shivprasad Shahajirao Deshmukh
Adina Dirlea
Falk Ehmann
Hans-Georg Eichler
Alan Fairlamb
Gudrun Fridgeirsdottir
Alvaro Goyanes
Sara Gualdoni
Mike Hann
Tomás S. Harrington
Rob Hemmings
Brian Henry
Matthew Hopgood
Chahinez Houacine
Iain Hrynaszkiewicz
Craig Johnston
Alison Keating
Chris Knox
Jayne Lawrence
Katharine Locke
Felipe Lopez
William Marks
Parastoo Masoomi
Helen Musther
Adam Nelson
Ricky Patel
Munir Pirmohamed
Bahijja Raimi-Abraham
Paulina Rakowska
Julia Robinson
Amin Rostami-Hodjegan
Malcolm Rowland
Mais Saleh
Michael Schwertner
Ivana Silva
Kamalinder K Singh
Duncan Stacey
Mo Tighsazzadeh
Geoffrey Tucker
Piet Van Der Graaf
Hugh Verrier
Paolo Vicini
Luke Vinter

Number of participants from United Kingdom: 56

United States of America

Andrea Adamo
Moji Christianah Adeyeye
Murray Aitken
Ralph Altiere
Zane Arp
Leslie Benet
Guru Betageri
Yuemin Bian
Mark Bolgar
Christine Bowman
James Brasseur
Tjerk Bueters
Rebecca Carrier
Rosa Chan
Jae Chang
Lekhram Changoer
Brian Cicali
Rebecca Davies
Hartmut Derendorf
Binodh Desilva
Shawn Engels
William Evans
Kathy Giacomini
Chao Han
Dan Hartman
Shiew Mei Huang
Brian Jensen
Brian Kennedy
Steven Kern
Frank Lee
Yugyung Lee
Larry Liberti
Shufang Liu
Viera Lukacova
Murray Lumpkin
Don Mager
Walter Marlowe
Stacey May
Philip Mayer
Scott Mcneil
Valeri Melekhov
Jay Mettetal
Erik Michalson
Marilyn Morris
Willem Mulder
Cynthia Musante
Svein Øie
Hideaki Okochi
Giovanni Pauletti
Chad Pickens
Chetan Pujara
Mary Relling
Klaus Romero
Stephan Schmidt
Steven Schwendeman
Vinod Shah
Anton Simeonov
Jasleen Sodhi
Robert Straka
Keith Tanner
Mirjam Trame
Konstantin Tsinman
Peter Warner
Alan Wolfe
Hsin-Fang Wu
Songlin Xue
Chang-Guo Zhan
Lei Zhang
Yuanchao (Derek) Zhang
Fang Zheng

Number of participants from United States: 71

Uruguay

Washington Díaz

Number of participants from Uruguay: 1


Participants registered online up until 18 April 2017.

An updated participants list can be found in the PSWC 2017 app.

Under the patronage of
His Highness Sheikh Hamdan bin Rashid Al Maktoum
Deputy Ruler of Dubai, Minister of Finance and President of the Dubai Health Authority

DUPHAT

23rd مؤتمر ومعرض دبي الدولي للصيدلة والتكنولوجيا
Dubai International Pharmaceuticals & Technologies Conference & Exhibition



27 February - 1 March 2018

مركز دبي الدولي للمؤتمرات والمعارض
Dubai International Convention & Exhibition Centre

duphat.ae

JOIN THE LARGEST PHARMACEUTICAL EVENT IN THE MIDDLE EAST

duphat.UAE

duphat_UAE

#DUPHAT

INDEX Conferences & Exhibitions Organisation Est.
INDEX Holding Headquarters, Road # D-62, Opposite Nad Al Hamar, P.O.Box: 13636, Dubai, UAE
Tel: +971 4 520 8888, Fax: +971 4 338 4193, E-mail: info@duphat.ae

Enjoying PSWC 2017?

www.aaps.org/PSWC

EXPAND YOUR COMMUNITY AT THE

2017 AAPS ANNUAL MEETING AND EXPOSITION

Dynamic Programming Themes:

- Advanced Formulation Characterization Approaches
- Patient-Centered Innovations in Healthcare Technology
- Products for Pediatrics: It's Not Child's Play
- Improving Inter-organization Collaboration
- Cancer Moonshot: Emerging Modalities for Oncology



PLUS all the targeted programming you expect

- Latest Research
- Community of Scientists
- Taking Theory to Application
- Over 400 Supplier Resources

2017 AAPS ANNUAL MEETING AND EXPOSITION

12–15 NOVEMBER 2017 | SAN DIEGO CONVENTION CENTER | SAN DIEGO | USA

IMPORTANT DATES

Late May	REGISTRATION OPENS
June 14	POSTER ABSTRACT SUBMISSION DEADLINE
June 15	HOT TOPIC SUBMISSION DEADLINE

aaps® American Association of Pharmaceutical Scientists


Recipharm
good for business
We don't just manufacture pharmaceuticals. We develop solutions for you.
DEVELOPMENT
Synthetic chemistry | Analytical & formulation development | Clinical supply
MANUFACTURING
APIs | Finished products | Packaging | Serialisation
recipharm.com



a sweden BIO event, produced by bionordic

photographer: camille_sonally

official conference hosts

invest in skåne
part of business region skåne

COPENHAGEN CAPACITY

City of Malmö

BIO PEOPLE
Denmark's Life Science Cluster

event in skåne
part of business region skåne

GREATER COPENHAGEN

medicon valley alliance
Creating Opportunities

MEDEON

register at
www.nlsdays.com

Leadership for good starts here

THE UNIVERSITY OF SYDNEY

Chair of Clinical Pharmacy (RPAH)

Reference no. 117/0117

Closing date: 30 June 2017

The Faculty of Pharmacy at the University of Sydney enjoys a prestigious, internationally-recognised reputation and fosters a culture of teaching and research excellence, advancing studies in the field of pharmacy through undergraduate and postgraduate degrees and internationally competitive research programs.

We are currently seeking to appoint an outstanding academic to the role of Chair of Clinical Pharmacy to join us and provide leadership and support for teaching and research activities at the University and Royal Prince Alfred Hospital. You will be appointed at the professorial level and responsible for professional and industry research collaborations, focusing on the faculty's core research themes, as well as building partnerships with relevant industry, academic and health-related organisations.

In addition to your distinguished teaching and research record, you will also have experience obtaining competitive research funding coupled with a strong commitment to the development of education programs within the broad areas of pharmacy.

This is a wonderful opportunity to join the Faculty of Pharmacy at the University of Sydney and Royal Prince Alfred Hospital and contribute to leadership in clinical pharmacy.

For more information and to apply, search by the reference number at **sydney.edu.au/recruitment**

A1

Drug Delivery & Targeting Sciences and Formulation & Manufacturing Sciences

SHORT COMMUNICATION SESSON

A1 | TRANSPORTERS AND PERMEABILITY

1014
Transporter protein expression and localization in the human retinal pigment epithelium cell models
Laura Pelkonen /
University of Eastern Finland, Finland
–
1015
How is mucus influencing on drug permeability in the PVPA?
Margherita Falavigna /
University of Tromsø, Norway
–
1091
Effect of amino acid-based surfactants on Caco-2 cell permeability of macromolecular drugs
Diego Romano Perinelli /
University of Camerino, Italy
–
1027
The use of Caco-2 cells to evaluate drug absorption from lipid-based formulations
Janneke Keemink /
Uppsala University, Sweden

A2

Drug Delivery & Targeting Sciences and Formulation & Manufacturing Sciences

SHORT COMMUNICATION SESSON

A2 | INTESTINAL ABSORPTION AND ANTIBIOTIC DRUG DELIVERY

1085
Understanding the link between composition, structure formation and absorption of milk during digestion
Anna C. Pham /
Monash Institute of Pharmaceutical Sciences, Australia
–
1057
The effect of sparkling water on intraluminal formulation behaviour and systemic drug performance in man
Jens Van Den Abeele /
KU Leuven, Belgium
–
1065
Examining the interaction of mesoporous silica particles with lipid digestion components
Kellie May /
Monash Institute of Pharmaceutical Sciences, Australia
–
1046
In vitro lipolysis of drug loaded lipid-based formulations with solid-state characterization of drug precipitate
Linda C. Alskär /
Uppsala University, Sweden

A3

Drug Delivery & Targeting Sciences and Formulation & Manufacturing Sciences

SHORT COMMUNICATION SESSON

A3 | DRUG DELIVERY SYSTEMS AND PHARMACOKINETICS

1043
Synthesis and characterization of PEGylated polyethyleneimine-entrapped gold nanoparticles by self-reduction
Shayesteh Amin /
Shiraz University of Medical Sciences, Iran
–
1028
In Vitro Cytotoxicity and In Vivo Biodistribution of Simvastatin-loaded Lecithin/Chitosan Nanoparticles: Nasal Region as an Appealing Route for Brain Delivery
Adryana Clementino /
National Council for Scienctific and Technological Development, Brazil
–
1093
Effects of silymarin on the pharmacokinetics of carbamazepine, oxcarbazepine, phenytoin and their main metabolites in rats
Ana Filipa Ferreira /
University of Beira Interior, Portugal
–
1023
Pharmacokinetic evaluation of doxorubicin containing lipiodol-based emulsion and drug-eluting beads used in the treatment of intermediate hepatocellular carcinoma
Ilse Dubbelboer /
Uppsala University, Sweden

B1

Drug Design, Fundamental & Translational Sciences

SHORT COMMUNICATION SESSON

B1 | MODELING AND SYNTHESIS

1011
Design, Synthesis and Testing of novel small molecule inhibitors of S-phase Kinase-Associated Protein 2
Ran Liu /
University of Sydney, Australia
–
1089
Engineering of KR-12 derived from human host defence peptide LL-37 into stable, selective and potent antimicrobial drug lead
Taj Muhammad /
Uppsala University, Sweden
–
1073
A semi-mechanistic PK/PD model to elucidate levofloxacin-induced killing and resistance development of Escherichia coli
Eva Goebgen /
Institute of Pharmacy Germany
–
1069
Evaluating predictors of paclitaxel-associated peripheral neuropathy: a pharmacodynamic modelling approach
Francis Williams Ojara /
Freie Universitaet Berlin, Germany

B2

Drug Design, Fundamental & Translational Sciences

SHORT COMMUNICATION SESSON

B2 | PERMEABILITY AND CELLS

1025
Measuring and modelling pH-profile of membrane permeability
Mare Oja /
University of Tartu, Estonia
–
1038
Influence of lipophilicity and hydrogen bond formation on passive diffusion of small-molecule drugs across hexadecane-based artificial cell membranes
Ursula Thormann /
Uppsala University, Sweden
–
1062
Factors affecting intestinal drug permeation in-vitro: rat intestinal tissue vs. artificial membrane
Danny Riethorst /
KU Leuven, Belgium
–
1033
Attach or perish: culture morphology and causal factors for variable attachment properties of cryopreserved human hepatocytes
Magnus Ölander /
Uppsala University, Sweden

C1

Regulatory Sciences and Science-based Practice

SHORT COMMUNICATION SESSON

C1 | REGULATORY, PRACTICE AND MANUFACTURING

1080
Pharmacists' activities to minimise medication waste: an international survey
Charlotte Bekker /
Utrecht University, Netherlands
–
1086
Digital Patient Support Tools for Improved Cardiovascular Disease Rehabilitatio
Alexander Mammoo /
AstraZeneca, Sweden
–
1087
Impact of Different MIC Distribution in Determining Empirical Vancomycin Continuous Infusion Dosing in Critically Ill Population
Eko Setiawan /
University of Surabaya, Indonesia
–
1070
Designing relevant test methods to characterise the disintegration properties of rapidly disintegrating tablets
Charlotte Bain /
AstraZeneca, United Kingdom

SATURDAY MAY 20

TRACK A	TRACK B	TRACK C
Fundamental & Translational Sciences & Targeting Sciences	**Drug delivery, Formulation & Manufacturing Sciences**	**Regulatory Sciences & Science-based Practics**

14:00 - 17:30 SHORT COMMUNICATIONS

TRACK A

14:00 - 15:30
A1 | ROOM B | B22
Transporters and permeability
CHAIR
Elizabeth de Lange / *Leiden University*
CO-CHAIR
Amal Kamal Abdel-Aziz / *Ain Shams University*

16:00 - 17:30
A2 | ROOM B | B22
Intestinal absorption and antibiotic drug delivery
CHAIR
Pieter Stolk / *Utrecht University*
CO-CHAIR
Amani Al-Hayali / *Luleå University of Technology*

TRACK B

14:00 - 15:30
B1 | ROOM B | B41
Modeling and synthesis
CHAIR
Anja Sandström / *Uppsala University*
CO-CHAIR
Irina Elena Antonescu / *University of Southern Denmark*

16:00 - 17:30
B1 | ROOM B | B41
Permeability and cells
CHAIR
Chamari Hettiarachchi / *University of Colombo*
CO-CHAIR
Diego Romano Perinelli / *University of Camerino*

TRACK C

14:00 - 15:30
C1 | ROOM B | B42
Regulatory, practice and manufacturing
CHAIR
Bente Steffansen / *University of Southern Denmark*
CO-CHAIR
Maria Badal Tejedor / *Research Insitutes of Sweden*

16:00 - 17:30
A3 | ROOM B | B42
Drug delivery systems and pharmacokinetics
CHAIR
TBA
CO-CHAIR
Javier Morales / *University of Chile*

FIKA BREAK

SUNDAY MAY 21

09:00 - 10:30 PLENARY SESSION

LECTURE HALL B | B8

***Moderator** / Erik Melander / Uppsala University*

09:00 – 09:45

Plenary lecture

Joseph Nicolazzo / Monash University

Helping shape the future of science and your career by serving your professional community

–

09:45 – 10:30

Plenary lecture

Eeva Teräsalmi / FIP Vice President

Green Pharmacy from research to practice – taking responsibility for the environmental impact of medicines

10:30 - 11:30 FIKA BREAK AND POSTER VIEWING

11:30 - 12:45 PLENARY ENDING CEREMONY

LECTURE HALL B | B8

***Moderator** / Caroline Alvebratt / Uppsala University*

11:30 – 12:15

Plenary lecture

Steven Kern / Bill and Melinda Gates Foundation

Thinking beyond your thesis – pharmaceutical research & development for global health impact

–

12:15 – 12:45

Award ceremony and closing remarks

13:30 BUS DEPARTURES TO STOCKHOLM

LUNCH



FRIDAY MAY 19

12:00 - 14:00 ARRIVAL AND REGISTRATION

14:00 - 16:00 PLENARY OPENING CEREMONY

LECTURE HALL B | B8

***Moderator** / Rebecka Isaksson / Uppsala University*

14:00 – 14:40

Welcome and opening of conference

Carmen Peña / FIP President

Tatsuro Irimura / FIP Chair Board of Pharmaceutical Sciences

Dominique Jordan / FIP Chair Board of Pharmaceutical Practice

Eva Åkesson / Vice-Chancellor of Uppsala University

Göran Alderborn / Dean at the Faculty of Pharmacy, Uppsala University

–

14:40 – 15:20

Plenary lecture

Kathy Giacomini / UCSF School of Pharmacy

Endogenous Roles of Drug Transporters

–

15:20 – 16:00

Plenary lecture

Thomas Lönngren / NDA Group AB

Global drug development from a regulatory and market access perspective – hurdles and opportunities



18:00 - CONFERENCE DINNER & PARTY

AT NORRLANDS STUDENT NATION / VÄSTRA ÅGATAN / 753 09 UPPSALA

SATURDAY MAY 20

TRACK **A**	TRACK **B**	TRACK **C**
Fundamental & Translational Sciences & Targeting Sciences	**Drug delivery, Formulation & Manufacturing Sciences**	**Regulatory Sciences & Science-based Practics**

09:00 - 09:45 KEYNOTE

ROOM B | B22
CHAIR
Joseph Nicolazzo / Monash University
CO-CHAIR
Rob van Wijk / Leiden University

Rada Savic
University of California San Francisco

Use of pharmacometrics and data science to combat global health problems

ROOM B | B41
CHAIR
Stacey May / American Association of Pharmaceutical Scientists
CO-CHAIR
Sayan Mitra / University of Sydney

Jan Kihlberg
Uppsala University

Drug discovery beyond the rule of 5 – How to design cell permeable ligands for difficult targets

ROOM B | B42
CHAIR
Bente Steffansen / University of Southern Denmark
CO-CHAIR
Alexander Mammoo / AstraZeneca

Staffan Folestad
Astra Zeneca R&D

Provision of innovative medicines for the individual – Need for patient centric engineering in global health

10:00 - 12:00 WORKSHOP SESSIONS

WORKSHOPS – PART 1

Excellence in science
ROOM A1 | 104B
Elizabeth de Lange / Leiden University
–
Communicate science
ROOM A7 | 114
Stacey May / AAPS

Grant application
ROOM A1 | 112B
Krister Halldin / Uppsala University
–
Entrepreneurship / Pitch your idea
ROOM A7 | 103
Moa Fransson / UU Innovation
–
Pedagogical skills
ROOM A2 | 122A
Don Mager / University of Buffalo

Patenting
ROOM A7 | 108
Olivia Tolan & Pontus Skråmstadius / UU Innovation

Regulatory framework
ROOM A2 | 108A
Pieter Stolk / Utrecht University

FIKA BREAK

WORKSHOPS – PART 2

12:00 - 14:00 LUNCH & POSTER VIEWING

13.30-14:00 The Swedish Pharmaceutical Society Award *for* ***Best Thesis in Galenic Pharmacy and Biopharmacy 2016*** *(GaBi-priset)*
Award ceremony for, and lecture by, the recipient Dr. Shalini Singh
ROOM B | B42

WELCOME TO **YSC 2017**

'Improving your skills in drug discovery, developments and clinical usage'

Welcome to Uppsala, home to the oldest university in Scandinavia, founded in 1477. This vibrant academic city possesses many historic sites as well as cutting edge research. The city is located a short train ride away from the PSWC in Stockholm.



Brass Statue 'DNA Molecule'
Biomedicinskt Centrum (BMC), Uppsala
Photo: Ulrika Wallin

At the YSC, young scientists will be given the opportunity to present their research in three different tracks:

TRACK **A**
Fundamental & Translational Science & Targeting Sciences

TRACK **B**
Drug delivery, Formulation & Manufacturing Sciences

TRACK **C**
Regulatory Sciences & Science-based Practice

In addition to these tracks, there will be workshops where you as an attendee will be provided with training that can sharpen your skills and help you towards successful research. By discussing pressing issues with your peers and key people in medicines research we hope that you, the next generation of pharmaceutical scientists, will be given the tools to tackle the challenges of the future.



Biomedicinskt Centrum (BMC), Uppsala
Photo: Ulrika Wallin

UPPSALA UNIVERSITET

Venue
Uppsala University
Biomedicinskt Centrum
Husargatan 3
75 123 Uppsala
Sweden

YSC WORKSHOP **TOPICS**

Communicate science

Interacting with society and spreading knowledge to the public is an important task for the scientific community which is not easily fulfilled. The public knowledge about a specific subject can be very diverse; however, it is of great importance that you, as a researcher, can overcome this knowledge barrier. This workshop aims to help you better communicate your science beyond the scientific environment.

Entrepreneurship / Pitch your idea

Entrepreneurship is not only the capacity to develop, organize and manage business to make a profit, it is a way of thinking and acting for creative problem solving with passion and persistence. The concept is closely related to the ability to explain complex ideas and complicated concepts in a condensed and straightforward manner. Whether it is to sell your idea to a potential investor or explain your research to a future employer, all researchers eventually encounter a situation where they only have a few minutes to explain and attract interest for their research.

Excellence in science

Conducting trustworthy experiments is the core of all research; however in academia good laboratory practice (GLP) is rarely applied. GLP is a practice to ensure high quality pre-clinical research, so that the data presented in articles and patents reflect the results obtained during the experiments.
Data management and handling has become increasingly important in the scientific community, correlating to the discussion of reproducibility of results, which in recent years has become a hot topic.

Grant application

As a young researcher funding is a key aspect to move further in your career with post-doc positions, and later for initiating your own research group. Applying for grants can be difficult; however, in this session an overview of the process will be presented focusing on grants for young scientists, e.g. PhD students and post-docs.

Patenting

It is important to be aware of your rights, and how to reason when the issues of patenting comes into question, as published science cannot be granted a patent. This session will provide you with the main issues to be considered before applying for patent to ensure the protection of the rights and welfare of people who participate in research projects.

Pedagogical skills

Pedagogy is the art of teaching, and a necessity within the academic environment. In this session, you will be given the opportunity to develop your skills as a teacher in a laboratory/seminar environment. The focus of this session will be how to activate and engage students, and how to effectively introduce students to new concepts and ideas.

Regulatory framework

Legal and economic issues that surround pharmaceutical products constantly increase in complexity due to global trading. This session will address the requirements and procedures for the marketing authorisation of medicinal products for human use, as well as the rules for the constant supervision of products after they have been authorised.

YSC

UPPSALA
19-21 MAY **2017**

Young Scientist Satellite Conference

Improving your skills for research in drug discovery, drug development and clinical usage

The world of medicines research and pharmaceutical sciences is quickly evolving with systems biology and new technology expanding our view on disease and treatment. At the core of this evolution are tomorrow's scientists: the PhD-students and post-docs.

The Young Scientist Satellite Conference of the PSWC is an exciting occasion for future scientists to meet, discuss and present their science in many forms such as oral sessions, poster sessions and workshops. This will also be an opportunity to gain knowledge from the experts attending the Pharmaceutical Sciences World Congress.

UPPSALA
UNIVERSITET

